diclofenac has been researched along with Arthritis, Rheumatoid in 304 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of 4 pivotal multicentre double-blind trials demonstrating the clinical efficacy of diclofenac/misoprostol in the treatment of rheumatoid and osteoarthritis are reviewed." | 10.17 | Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. ( Downie, WW, 1993) |
| "To examine elevations in levels of serum glutamic oxaloacetic transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations for the occurrence of these elevations." | 10.17 | Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. ( Anderson, W; Furst, DE, 1993) |
| "Diclofenac suppository, a non-steroidal anti-inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain." | 9.17 | A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. ( Arimori, K; Chosa, E; Fujita, K; Kawai, K; Nishio, T; Ogata, K; Setoguchi, N; Takamura, N; Tokunaga, J; Yamamoto, R, 2013) |
| " This pilot clinical study evaluated the safety and effectiveness of curcumin alone, and in combination with diclofenac sodium in patients with active rheumatoid arthritis (RA)." | 9.16 | A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. ( Chandran, B; Goel, A, 2012) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 9.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)." | 9.13 | Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008) |
| "To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis." | 9.11 | Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. ( Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ, 2004) |
| "Methotrexate and nonsteroidal antiinflammatory drugs are frequently coadministered in the treatment of rheumatoid arthritis (RA)." | 9.11 | Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ( Branson, JM; Chales, GH; Hartmann, SN; Juvin, RR; Lafforgue, P; Le Parc, JM; Meyer, OC; Milosavljev, S; Rordorf, CM; Tavernier, CG, 2004) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 9.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid arthritis (RA)." | 9.10 | Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. ( Pavelka, K; Recker, DP; Verburg, KM, 2003) |
| " Health-care resource utilization and the costs of these resources were compared from the perspective of the UK National Health Service using data obtained in a 6-month clinical trial of oral valdecoxib 20 mg once daily and diclofenac 75 mg twice daily for the symptomatic treatment of rheumatoid arthritis." | 9.10 | Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. ( Niculescu, L; Peña, B; von Scheele, B; Wong, J, 2003) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 9.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 9.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 9.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "The efficacy and tolerability of aceclofenac, a new non-steroidal anti-inflammatory drug (NSAID) was compared to that of ketoprofen in a multicentre, double-blind, prospective, randomized study of 3-months duration in patients with rheumatoid arthritis." | 9.08 | Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. ( Ansoleaga, JJ; Gijón-Baños, J; Martín-Mola, E, 1995) |
| "We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients." | 9.08 | Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen. ( Carrabba, M; Galante, A; Manfredi, B; Panerai, AE; Pisati, R; Sacerdote, P, 1995) |
| "The efficacy and tolerability of aceclofenac (100 mg bid; n = 109), a new non-steroidal anti-inflammatory agent, was compared to that of indomethacin (50 mg bid; n = 110) in a multi-centre, 12-week, randomized, double-blind clinical trial in patients with rheumatoid arthritis." | 9.08 | The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. ( Bowdler, J; Kornasoff, D; Maisenbacher, J; Raber, A, 1996) |
| "The efficacy and safety of 100 mg aceclofenac twice daily was investigated in 73 patients with active rheumatoid arthritis in a multi-centre, double blind, randomised, parallel group, placebo controlled study over a period of 4 weeks." | 9.08 | Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory. ( Balaguer, XG; Hunter, JA; Parnham, MJ, 1996) |
| "To compare the efficacy and safety of aceclofenac (AC) and tenoxicam (TX) in the treatment of rheumatoid arthritis (RA), a multicentric parallel, randomized, double-blind trial of three months duration was performed in 292 patients: 145 were randomized to the AC treatment group and 147 to the TX treatment group." | 9.08 | Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. ( Alonso-Ruiz, A; Ansoleaga, JJ; Perez-Ruiz, F, 1996) |
| "(1) To characterize potential changes in diclofenac pharmacokinetics and renal function in patients with rheumatoid arthritis (RA) treated with diclofenac and cyclosporine; (2) to prospectively collect longitudinal safety data during use of this drug combination." | 9.08 | Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. ( Alten, R; Genth-Stolzenburg, S; Guerret, M; Kovarik, JM; Kurki, P; Markert, E; Mueller, E; Zeidler, H, 1996) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 9.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| "The objective of our study was to estimate the cost effectiveness of treatment with a fixed-dose combination of diclofenac and misoprostol compared with diclofenac monotherapy in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients." | 9.08 | The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. ( Al, MJ; Michel, BC; Rutten, FF, 1996) |
| "A double-blind, randomised, parallel-group study was conducted in eight countries to compare the efficacy of a fixed combination of diclofenac sodium (50 mg) and misoprostol (200 mcg) with a fixed combination of diclofenac sodium (50 mg) and placebo in treating the signs and symptoms of rheumatoid arthritis (RA)." | 9.07 | Double-blind comparison of the efficacy of diclofenac/misoprostol and diclofenac in the treatment of rheumatoid arthritis. ( Beaulieu, A; de Queiroz, MV; Geis, S; Kruger, K; Stead, H; Woods, E, 1994) |
| "The pharmacodynamics and pharmacokinetics of 75 mg resin-bound diclofenac (resinate) were compared with enteric-coated tablets containing 75 mg of diclofenac in a double-blind randomized crossover trial in 16 patients suffering from rheumatoid arthritis." | 9.07 | The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ( Kurowski, M; Menninger, H; Pauli, E, 1994) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 9.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "The efficacy and tolerability of a new, controlled-release indomethacin (75 mg) tablet was compared to that of a sustained-release diclofenac sodium (100 mg) tablet in 84 patients with rheumatoid arthritis." | 9.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial. ( Crowley, B; Hamill, JJ; Lyndon, S; McKellican, JF; Miller, AJ; Williams, P, 1990) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 9.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 9.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 9.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations." | 9.06 | Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986) |
| "In a six-week, double-blind, randomized, multicenter clinical trial, the efficacy and safety of 150 mg/day of diclofenac sodium and a placebo were compared in 182 patients with active definite or classical rheumatoid arthritis." | 9.06 | Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis. ( Weisman, MH, 1986) |
| "Piroxicam and diclofenac were compared for 4 weeks in an open parallel study in 20 rheumatoid arthritis patients each." | 9.05 | [Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac]. ( Rohde, J; Schwegler, F; Standel, W, 1980) |
| "A six-month single-blind, randomized parallel group study comparing the effects of fenclofenac and diclofenac in 63 patients with rheumatoid arthritis is described." | 9.05 | Fenclofenac and diclofenac in the treatment of rheumatoid arthritis. ( Bedi, SS; Eberl, R; Million, R; Silas, AM, 1984) |
| "The efficacy and tolerability of 100 mg suppositories of diclofenac sodium (Voltaren) and indomethacin were investigated in relieving symptoms of rheumatoid arthritis." | 9.05 | Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis. ( Valindas, E; Wafin, F; Wuolijoki, E, 1984) |
| "A short-term trial has been performed under double-blind conditions in 50 adult patients with rheumatoid arthritis to compare diclofenac sodium (Voltaren) with both indomethacin and placebo for efficacy and tolerability." | 9.04 | Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. ( Dürrigl, T; Miko, M; Pucar, I; Vitaus, M, 1975) |
| "150 mg/day sodic diclofenac was found particularly active in subjects with diathetic rheumatism and arthrosis." | 9.04 | [Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases]. ( Durante, F, 1978) |
| "In a double-blind crossover trial conducted on a multicentre basis, 109 patients with "classic" or "definite" rheumatoid arthritis were treated for two weeks with diclofenac sodium (Voltaren, 25 mg t." | 9.04 | Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: a double-blind multicentre study. ( Mutru, O; Penttilä, M; Pesonen, J; Salmela, P; Sonck, T; Suhonen, O, 1978) |
| "A report is given on a long-term controlled trial in which diclofenac sodium (Voltaren) was compared with indomethacin in 36 patients with rheumatoid arthritis, both drugs being administered in a dosage of 75-125 mg daily." | 9.04 | The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. ( Bijlsma, A, 1978) |
| "A five-centre double-blind crossover trial of two two-week periods using diclofenac and indomethacin showed that both drug groups (51 patients) with rheumatoid arthritis responded similarly in relation to pain scores and morning stiffness." | 9.04 | Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis. ( Barnes, CG; Berry, H; Carter, ME; Downie, WW; Fowler, PD; Moll, JM; Perry, JD; Sawaf, MS; Wright, V, 1979) |
| " In a two-week double-blind study, diclofenac was compared with indomethacin in 43 outpatients with osteoarthritis or rheumatoid arthritis." | 9.04 | An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. ( Cash, HC; McMahon, MF, 1979) |
| " This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA)." | 8.91 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. ( Guyot, P; Karabis, A; Moore, RA; Nixon, RM; Pandhi, S; van Walsem, A, 2015) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 8.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 8.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 8.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Methotrexate is one of the most commonly used drugs in autoimmune disorders like rheumatoid arthritis." | 7.88 | Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury. ( Biju, IK; Manappallil, RG; Peringat, J; Prasan, D, 2018) |
| "The aim of present research was to complex aceclofenac with lysine (LYS) and the developed aceclofenac-LYS cocrystal was encapsulated in lipid bilayers of liposomes by employing dual carrier approach for the treatment of pain-related disorders in rheumatoid arthritis (RA)." | 7.85 | Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic attributes: a preclinical study. ( Garg, NK; Goni, VG; Kapil, N; Katare, OP; Pareek, A; Raza, K; Saini, MK; Sharma, G; Thakur, K, 2017) |
| "The use of non-steroidal anti-inflammatory drugs like diclofenac in the third trimester of pregnancy can cause severe side effects, in particular oligohydramnios, premature closure of ductus arteriosus, and fetal kidney damage." | 7.81 | Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. ( Entezami, M; Kayser, A; Schaefer, C; Scherneck, S; Schöpa, FL; Weber-Schoendorfer, C, 2015) |
| "Pineal hormone melatonin (1 and 5 mg/kg) and diclofenac (8 mg/kg) significantly limited hematologic indices of inflammation and immunologic reactivity in rats with experimental adjuvant arthritis." | 7.80 | [Comparative study of the influence of melatonin and diclofenac on some hematologic indices of experimental rheumatoid arthritis in rats]. ( Arushanian, ÉB; Ivanova, VN; Lomonosova, KV; Naumov, SS, 2014) |
| " Aceclofenac was used as a model drug owing to its potential therapeutic efficacy in rheumatoid arthritis." | 7.79 | Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. ( Ramasamy, T; Ruttala, HB; Shanmugam, S; Umadevi, SK, 2013) |
| " The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis." | 7.73 | Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. ( Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L, 2006) |
| "We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)." | 7.73 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006) |
| "A 73-year-old patient developed severe nephrotic syndrome with minimal glomerular lesions 6 weeks after tiopronin therapy was initiated." | 7.70 | [Tiopronin-induced nephrotic syndrome with minimal glomerular lesions]. ( Duvic, C; Hérody, M; Lecoules, S; Nédélec, G, 1999) |
| "The aim of this study was to demonstrate metabolic changes in the small joints of the hand due to rheumatoid arthritis by means of 31-phosphorus spectroscopy." | 7.69 | [Rheumatoid arthritis of the hand. The initial results with 31-phosphorus MR spectroscopy]. ( Bollow, M; Braun, J; König, H; Schilling, A; Wacker, F; Wolf, KJ, 1994) |
| "Effects of the nonsteroidal anti-inflammatory drug, diclofenac, on stimulated monocyte superoxide production were assessed directly in vitro and following treatment of patients with rheumatoid arthritis ex vivo." | 7.68 | Diclofenac inhibits monocyte superoxide production ex vivo in rheumatoid arthritis. ( Adamson, H; Bell, AL; Kirk, F; McCaigue, MD; Rotman, H, 1991) |
| "Ninety patients with active rheumatoid arthritis took part in a cross-over trial comparing diclofenac sodium, diflunisal and naproxen." | 7.66 | Diclofenac sodium, diflunisal and naproxen: patient preferences for anti-inflammatory drugs in rheumatoid arthritis. ( Dieppe, PA; Huskisson, EC; Jones, H; Scott, J, 1982) |
| "The development of membranous glomerulonephritis in a 51 year old patient suffering from rheumatoid arthritis suggested drug toxicity, and particularly of a recently developed anti-inflammatory agent, diclofenac." | 7.66 | [Membranous glomerulonephritis during rheumatoid arthritis. Probable toxicity of diclofenac (author's transl)]. ( Ducret, F; Pichot, C; Pointet, P, 1980) |
| "Diclofenac 150 mg was superior to placebo for 4 of 5 primary efficacy measures (all but swollen joint count; p < 0." | 6.70 | Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. ( Fleischmann, R; Furst, DE; Greenwald, M; Hall, DB; Kolba, KS; Roszko, PJ; Roth, S; Silverfield, J, 2002) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Tenidap is a novel anti-rheumatic drug that combines cytokine modulation with cyclo-oxygenase inhibition." | 6.68 | A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. ( Appelboom, T; Bolten, W; Breedveld, FC; Feely, J; Le Loët, X; Leeming, MR; Manthorpe, R; Marcolongo, R; Smolen, J; Wylie, G, 1995) |
| " Adverse events in both groups were minor, predominantly gastro-intestinal, and fewer patients tended to experience gastro-intestinal events on aceclofenac (13%) than on diclofenac (17%)." | 6.68 | A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. ( Ferrer, F; Marcolongo, R; Parnham, MJ; Pasero, G; Serni, U, 1995) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Diclofenac was detected in synovial fluid 2 h after dosing but at a lower level than in plasma." | 6.65 | Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. ( Crook, PR; Fowler, PD; John, VA; Shadforth, MF, 1983) |
| " Dosage was one tablet (25 mg diclofenac) three times daily during the first week." | 6.65 | Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial. ( Boardman, PL; Doreen, MS; Fowler, PD; Poole, PH, 1979) |
| "and naproxen 250 mg b." | 6.64 | Diclofenac sodium (Voltaren) and naproxen in the treatment of rheumatoid arthritis: a comparative double-blind study. ( Kajander, A; Martio, J, 1978) |
| " The clinical trial in patients with periarthritis of shoulder showed statistical equivalence of pain reduction, whether they were treated with phlogenzym or diclofenac." | 6.19 | [Reducing pain by oral enzyme therapy in rheumatic diseases]. ( Klein, G; Kullich, W, 1999) |
| "The results of 4 pivotal multicentre double-blind trials demonstrating the clinical efficacy of diclofenac/misoprostol in the treatment of rheumatoid and osteoarthritis are reviewed." | 6.17 | Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. ( Downie, WW, 1993) |
| "To examine elevations in levels of serum glutamic oxaloacetic transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations for the occurrence of these elevations." | 6.17 | Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. ( Anderson, W; Furst, DE, 1993) |
| "Diclofenac suppository, a non-steroidal anti-inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain." | 5.17 | A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. ( Arimori, K; Chosa, E; Fujita, K; Kawai, K; Nishio, T; Ogata, K; Setoguchi, N; Takamura, N; Tokunaga, J; Yamamoto, R, 2013) |
| " This pilot clinical study evaluated the safety and effectiveness of curcumin alone, and in combination with diclofenac sodium in patients with active rheumatoid arthritis (RA)." | 5.16 | A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. ( Chandran, B; Goel, A, 2012) |
| "Patients > or = 50 years with rheumatoid arthritis or osteoarthritis were randomly assigned to diclofenac (150 mg daily) or etoricoxib (60 or 90 mg daily)." | 5.14 | How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. ( Cannon, CP; Connors, LG; Curtis, SP; Goldkind, L; Laine, L; Yanqiong, Z, 2009) |
| "To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients." | 5.14 | Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2009) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 5.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)." | 5.13 | Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008) |
| "The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients." | 5.12 | Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006) |
| "To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis." | 5.11 | Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. ( Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ, 2004) |
| "Methotrexate and nonsteroidal antiinflammatory drugs are frequently coadministered in the treatment of rheumatoid arthritis (RA)." | 5.11 | Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ( Branson, JM; Chales, GH; Hartmann, SN; Juvin, RR; Lafforgue, P; Le Parc, JM; Meyer, OC; Milosavljev, S; Rordorf, CM; Tavernier, CG, 2004) |
| " In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily." | 5.11 | Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 5.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid arthritis (RA)." | 5.10 | Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. ( Pavelka, K; Recker, DP; Verburg, KM, 2003) |
| " Health-care resource utilization and the costs of these resources were compared from the perspective of the UK National Health Service using data obtained in a 6-month clinical trial of oral valdecoxib 20 mg once daily and diclofenac 75 mg twice daily for the symptomatic treatment of rheumatoid arthritis." | 5.10 | Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. ( Niculescu, L; Peña, B; von Scheele, B; Wong, J, 2003) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 5.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 5.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 5.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "The efficacy and tolerability of aceclofenac, a new non-steroidal anti-inflammatory drug (NSAID) was compared to that of ketoprofen in a multicentre, double-blind, prospective, randomized study of 3-months duration in patients with rheumatoid arthritis." | 5.08 | Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. ( Ansoleaga, JJ; Gijón-Baños, J; Martín-Mola, E, 1995) |
| "We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients." | 5.08 | Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen. ( Carrabba, M; Galante, A; Manfredi, B; Panerai, AE; Pisati, R; Sacerdote, P, 1995) |
| "The efficacy and tolerability of aceclofenac (100 mg bid; n = 109), a new non-steroidal anti-inflammatory agent, was compared to that of indomethacin (50 mg bid; n = 110) in a multi-centre, 12-week, randomized, double-blind clinical trial in patients with rheumatoid arthritis." | 5.08 | The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. ( Bowdler, J; Kornasoff, D; Maisenbacher, J; Raber, A, 1996) |
| "The efficacy and safety of 100 mg aceclofenac twice daily was investigated in 73 patients with active rheumatoid arthritis in a multi-centre, double blind, randomised, parallel group, placebo controlled study over a period of 4 weeks." | 5.08 | Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory. ( Balaguer, XG; Hunter, JA; Parnham, MJ, 1996) |
| "To compare the efficacy and safety of aceclofenac (AC) and tenoxicam (TX) in the treatment of rheumatoid arthritis (RA), a multicentric parallel, randomized, double-blind trial of three months duration was performed in 292 patients: 145 were randomized to the AC treatment group and 147 to the TX treatment group." | 5.08 | Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. ( Alonso-Ruiz, A; Ansoleaga, JJ; Perez-Ruiz, F, 1996) |
| "(1) To characterize potential changes in diclofenac pharmacokinetics and renal function in patients with rheumatoid arthritis (RA) treated with diclofenac and cyclosporine; (2) to prospectively collect longitudinal safety data during use of this drug combination." | 5.08 | Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. ( Alten, R; Genth-Stolzenburg, S; Guerret, M; Kovarik, JM; Kurki, P; Markert, E; Mueller, E; Zeidler, H, 1996) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 5.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| "Three randomized, blinded, multicenter studies, including one in general practice, evaluated the efficacy of combination diclofenac/misoprostol versus diclofenac or ibuprofen in a total of 1824 patients with rheumatoid arthritis (RA) or osteoarthritis (OA)." | 5.08 | Diclofenac/misoprostol: the European clinical experience. ( McKenna, F, 1998) |
| "In a randomized, double blind parallel group comparison the antiphlogistic and analgetic efficacy of high-dosed vitamin E (3 x 400 mg RRR-alpha-Tocopherolacetat/d) versus diclofenac-sodium has been investigated in hospitalized patients with established chronic rheumatoid arthritis." | 5.08 | [Effectiveness of vitamin E in comparison with diclofenac sodium in treatment of patients with chronic polyarthritis]. ( Brabant, T; Lorkowski, G; Petersen, G; Wittenborg, A, 1998) |
| "The objective of our study was to estimate the cost effectiveness of treatment with a fixed-dose combination of diclofenac and misoprostol compared with diclofenac monotherapy in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients." | 5.08 | The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. ( Al, MJ; Michel, BC; Rutten, FF, 1996) |
| "A double-blind, randomised, parallel-group study was conducted in eight countries to compare the efficacy of a fixed combination of diclofenac sodium (50 mg) and misoprostol (200 mcg) with a fixed combination of diclofenac sodium (50 mg) and placebo in treating the signs and symptoms of rheumatoid arthritis (RA)." | 5.07 | Double-blind comparison of the efficacy of diclofenac/misoprostol and diclofenac in the treatment of rheumatoid arthritis. ( Beaulieu, A; de Queiroz, MV; Geis, S; Kruger, K; Stead, H; Woods, E, 1994) |
| "Diclonate P (sodium diclofenac, Pliva, Zagreb) was used in the treatment of 74 patients with rheumatoid arthritis as the basic antirheumatic drug." | 5.07 | [Diclonate P in rheumatoid arthritis]. ( Alekberova, ZS; Balabanova, RM; Chichasova, NV; Ivanova, MM; Nasonov, EL; Tsvetkova, ES, 1994) |
| "The pharmacodynamics and pharmacokinetics of 75 mg resin-bound diclofenac (resinate) were compared with enteric-coated tablets containing 75 mg of diclofenac in a double-blind randomized crossover trial in 16 patients suffering from rheumatoid arthritis." | 5.07 | The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. ( Kurowski, M; Menninger, H; Pauli, E, 1994) |
| " One hundred patients, free from endoscopically detectable lesions of the gastroduodenal mucosa, affected either by rheumatoid arthritis or osteoarthritis, and candidates for NSAID therapy, were randomly allocated either to 200 mg sulglycotide three times daily (n = 50) or to an indistinguishable placebo (n = 50) for 4 weeks, together with standard NSAID administration (50 mg diclofenac three times daily (n = 50); 50 mg indomethacin three times daily (n = 50))." | 5.07 | Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study versus placebo in rheumatic patients. ( Ardizzone, S; Bianchi Porro, G; Caruso, I; Montrone, F; Petrillo, M, 1993) |
| "In a randomized, open-label, controlled, multicenter, 12-week study, the efficacy and safety of nabumetone (1,000-2,000 mg/day) versus diclofenac (100-200 mg/day), naproxen (500-1,500 mg/day), ibuprofen (1,200-3,200 mg/day), or piroxicam (10-20 mg/day) were evaluated in patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 5.07 | Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. ( DeLapp, RE; Morgan, GJ; Poland, M, 1993) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 5.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "One hundred patients with rheumatoid arthritis were entered into a randomised, double-blind, cross-over study of naproxen (500 mg b." | 5.07 | A clinical comparison of two leading non-steroidal anti-inflammatory drugs. ( Huskisson, EC; Scott, DL, 1991) |
| " Ninety-six patients with rheumatoid arthritis took single daily doses of controlled release naproxen (N), diclofenac S." | 5.07 | Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis. ( Huskisson, EC, 1991) |
| "In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks." | 5.07 | Efficacy of Arthrotec in the treatment of rheumatoid arthritis. ( Hannequin, JR, 1992) |
| "The efficacy and tolerability of a new, controlled-release indomethacin (75 mg) tablet was compared to that of a sustained-release diclofenac sodium (100 mg) tablet in 84 patients with rheumatoid arthritis." | 5.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial. ( Crowley, B; Hamill, JJ; Lyndon, S; McKellican, JF; Miller, AJ; Williams, P, 1990) |
| "In a double-blind clinical study, the analgesic effects of ibuprofen-lysinsalt and diclofenac were compared in 59 patients with rheumatoid arthritis." | 5.06 | [The dynamics of the analgesic effect of non-steroidal antirheumatic drugs. Ibuprofenlysinate versus diclofenac]. ( Pavelka, K; Trnavsky, K, 1989) |
| "Etodolac, a nonsteroidal anti-inflammatory drug (NSAID) of the pyranocarboxylic acid family, has been tested in international clinical trials as a therapy for rheumatoid arthritis (RA)." | 5.06 | International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. ( Briancon, D, 1989) |
| "A 14-day double-blind clinical study was conducted on 16 patients with clinically active rheumatoid arthritis to compare the effects of etodolac (600 mg daily) and diclofenac (150 mg daily)." | 5.06 | Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis. ( Bazzichi, L; Ciompi, ML; Marotta, G; Puccetti, L; Remorini, E, 1989) |
| " One trial involving 255 patients with rheumatoid arthritis (RA) was a 12-week, randomized controlled trail of diclofenac, naproxen, and aspirin." | 5.06 | Sensitivity of a health status measure to short-term clinical changes in arthritis. ( Anderson, JJ; Firschein, HE; Meenan, RF, 1989) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 5.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations." | 5.06 | Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986) |
| "In a six-week, double-blind, randomized, multicenter clinical trial, the efficacy and safety of 150 mg/day of diclofenac sodium and a placebo were compared in 182 patients with active definite or classical rheumatoid arthritis." | 5.06 | Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis. ( Weisman, MH, 1986) |
| " We have performed a crossover comparison of soluble aspirin, diclofenac and the two drugs in combination in patients with rheumatoid arthritis to determine whether this had clinical relevance." | 5.06 | A study to determine the clinical relevance of the pharmacokinetic interaction between aspirin and diclofenac. ( Bird, HA; Hill, J; Leatham, P; Wright, V, 1986) |
| "Piroxicam and diclofenac were compared for 4 weeks in an open parallel study in 20 rheumatoid arthritis patients each." | 5.05 | [Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac]. ( Rohde, J; Schwegler, F; Standel, W, 1980) |
| "A six-month single-blind, randomized parallel group study comparing the effects of fenclofenac and diclofenac in 63 patients with rheumatoid arthritis is described." | 5.05 | Fenclofenac and diclofenac in the treatment of rheumatoid arthritis. ( Bedi, SS; Eberl, R; Million, R; Silas, AM, 1984) |
| "The efficacy and tolerability of 100 mg suppositories of diclofenac sodium (Voltaren) and indomethacin were investigated in relieving symptoms of rheumatoid arthritis." | 5.05 | Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis. ( Valindas, E; Wafin, F; Wuolijoki, E, 1984) |
| "A short-term trial has been performed under double-blind conditions in 50 adult patients with rheumatoid arthritis to compare diclofenac sodium (Voltaren) with both indomethacin and placebo for efficacy and tolerability." | 5.04 | Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. ( Dürrigl, T; Miko, M; Pucar, I; Vitaus, M, 1975) |
| "150 mg/day sodic diclofenac was found particularly active in subjects with diathetic rheumatism and arthrosis." | 5.04 | [Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases]. ( Durante, F, 1978) |
| "In a double-blind, crossover study conducted in ten hospitalised patients suffering from active rheumatoid arthritis, the anti-inflammatory effect of diclofenac sodium (Voltaren) in a daily dosage of 125 mg was compared with that of placebo under strictly standardised conditions." | 5.04 | A study of the anti-inflammatory effect of Voltaren in patients with rheumatoid arthritis. ( Bijlsma, A; ten Pas, JG, 1978) |
| "In a double-blind crossover trial conducted on a multicentre basis, 109 patients with "classic" or "definite" rheumatoid arthritis were treated for two weeks with diclofenac sodium (Voltaren, 25 mg t." | 5.04 | Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: a double-blind multicentre study. ( Mutru, O; Penttilä, M; Pesonen, J; Salmela, P; Sonck, T; Suhonen, O, 1978) |
| "A report is given on a long-term controlled trial in which diclofenac sodium (Voltaren) was compared with indomethacin in 36 patients with rheumatoid arthritis, both drugs being administered in a dosage of 75-125 mg daily." | 5.04 | The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. ( Bijlsma, A, 1978) |
| "A five-centre double-blind crossover trial of two two-week periods using diclofenac and indomethacin showed that both drug groups (51 patients) with rheumatoid arthritis responded similarly in relation to pain scores and morning stiffness." | 5.04 | Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis. ( Barnes, CG; Berry, H; Carter, ME; Downie, WW; Fowler, PD; Moll, JM; Perry, JD; Sawaf, MS; Wright, V, 1979) |
| " In a two-week double-blind study, diclofenac was compared with indomethacin in 43 outpatients with osteoarthritis or rheumatoid arthritis." | 5.04 | An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. ( Cash, HC; McMahon, MF, 1979) |
| "To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 4.98 | Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. ( Feng, X; Mei, H; Tian, M; Zhang, W, 2018) |
| "In acute musculoskeletal pain (strains and sprains) with assessment at about seven days, therapies were diclofenac Emulgel (78% Emulgel, 20% placebo; 2 studies, 314 participants, NNT 1." | 4.95 | Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. ( Aldington, D; Bell, RF; Derry, S; Gaskell, H; Kalso, EA; Moore, RA; Phillips, T; Wiffen, PJ, 2017) |
| " This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA)." | 4.91 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. ( Guyot, P; Karabis, A; Moore, RA; Nixon, RM; Pandhi, S; van Walsem, A, 2015) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 4.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| " In randomised, controlled clinical trials, lumiracoxib 100 - 200 mg/day has been shown to be superior to placebo in patients with symptomatic osteoarthritis, with clinical efficacy similar to diclofenac 150 mg/day, celecoxib 200 mg/day or rofecoxib 25 mg/day." | 4.82 | Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. ( Bannwarth, B; Berenbaum, F, 2005) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 4.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 4.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "Methotrexate is one of the most commonly used drugs in autoimmune disorders like rheumatoid arthritis." | 3.88 | Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury. ( Biju, IK; Manappallil, RG; Peringat, J; Prasan, D, 2018) |
| "The aim of present research was to complex aceclofenac with lysine (LYS) and the developed aceclofenac-LYS cocrystal was encapsulated in lipid bilayers of liposomes by employing dual carrier approach for the treatment of pain-related disorders in rheumatoid arthritis (RA)." | 3.85 | Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic attributes: a preclinical study. ( Garg, NK; Goni, VG; Kapil, N; Katare, OP; Pareek, A; Raza, K; Saini, MK; Sharma, G; Thakur, K, 2017) |
| "Results of the CONDOR study suggest that in osteoarthritis and rheumatoid arthritis patients at elevated risk of gastrointestinal (GI) events, treatment with celecoxib, a cyclooxygenase (COX)-2 selective non-steroidal anti-inflammatory drug (NSAID), demonstrated significantly lower toxicity in the upper and lower (GI) tract when compared to the non-selective NSAID diclofenac plus a proton-pump-inhibitor (PPI), omeprazole." | 3.81 | How to mechanistically explain the CONDOR study data. ( Buttgereit, F; Spies, CM; Stemmler, E, 2015) |
| "The use of non-steroidal anti-inflammatory drugs like diclofenac in the third trimester of pregnancy can cause severe side effects, in particular oligohydramnios, premature closure of ductus arteriosus, and fetal kidney damage." | 3.81 | Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. ( Entezami, M; Kayser, A; Schaefer, C; Scherneck, S; Schöpa, FL; Weber-Schoendorfer, C, 2015) |
| "Pineal hormone melatonin (1 and 5 mg/kg) and diclofenac (8 mg/kg) significantly limited hematologic indices of inflammation and immunologic reactivity in rats with experimental adjuvant arthritis." | 3.80 | [Comparative study of the influence of melatonin and diclofenac on some hematologic indices of experimental rheumatoid arthritis in rats]. ( Arushanian, ÉB; Ivanova, VN; Lomonosova, KV; Naumov, SS, 2014) |
| " Aceclofenac was used as a model drug owing to its potential therapeutic efficacy in rheumatoid arthritis." | 3.79 | Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. ( Ramasamy, T; Ruttala, HB; Shanmugam, S; Umadevi, SK, 2013) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| " In both groups, the most frequently reported adverse events were gastrointestinal in nature, with abdominal pain reported most frequently (in 22." | 3.77 | Review of the safety of diclofenac/misoprostol. ( Gagnier, P, 1993) |
| " The five most commonly reported adverse events were abdominal pain by 23." | 3.77 | Overall safety of Arthrotec. ( Geis, GS, 1992) |
| " Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used in patients who suffer from painful autoimmune diseases such as rheumatoid arthritis." | 3.76 | Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. ( Bielańska, J; Comes, N; David, M; Felipe, A; González, T; Parra, D; Soler, C; Valenzuela, C; Villalonga, N, 2010) |
| "Etodolac has previously been reported to have an excellent safety profile." | 3.76 | A global safety evaluation of etodolac. ( Karbowski, A, 1989) |
| " The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis." | 3.73 | Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. ( Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L, 2006) |
| "We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)." | 3.73 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006) |
| "(1) For symptoms of rheumatoid arthritis (pain, joint stiffness), the reference treatment is a nonsteroidal antiinflammatory drug (NSAID) such as diclofenac or ibuprofen." | 3.72 | Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS. ( , 2003) |
| " The patient reported medication with diclofenac for rheumatoid arthritis." | 3.72 | [A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake]. ( Ablassmaier, B; Hartmann, J, 2004) |
| "To perform a modelled economic analysis of the efficacy and tolerability of aceclofenac in comparison with those of other nonsteroidal antiinflammatory drugs (NSAIDs) used in the treatment of common arthritic disorders including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis." | 3.71 | Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. ( Badia, X; Brosa, M; Martínez, E; Peris, F, 2001) |
| "A 73-year-old patient developed severe nephrotic syndrome with minimal glomerular lesions 6 weeks after tiopronin therapy was initiated." | 3.70 | [Tiopronin-induced nephrotic syndrome with minimal glomerular lesions]. ( Duvic, C; Hérody, M; Lecoules, S; Nédélec, G, 1999) |
| "To investigate the mechanisms of action underlying the anti-inflammatory effects of the nonsteroidal anti-inflammatory drug aceclofenac in humans, we studied the metabolism of aceclofenac in detail in primary cultured synovial cells of 10 patients with rheumatoid arthritis." | 3.70 | Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. ( Hashimoto, S; Kawai, S; Koshino, T; Matsumoto, T; Matsuzaki, T; Mizushima, Y; Okamoto, R; Yamazaki, R; Yokokura, T, 1999) |
| "Down-regulation of proMMP-1 and proMMP-3 production by 4'-hydroxy aceclofenac may contribute to the therapeutic effect of aceclofenac on rheumatoid arthritis and osteoarthritis." | 3.70 | A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. ( Hashimoto, S; Ito, A; Kawai, S; Matsuzaki, T; Mizushima, Y; Yamazaki, R; Yokokura, T, 2000) |
| "To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine." | 3.70 | [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000) |
| "Examination of gastric secretion in rheumatoid arthritis (RA) patients and its response to sodium diclophenak and indomethacine." | 3.70 | [Approaches to prediction of gastropathy development risk due to non-steroidal antiinflammatory drugs]. ( Alekseeva, AV; Murav'ev, IuV, 2000) |
| " Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients." | 3.69 | Safety profile of etodolac in the elderly population. ( Bacon, PA, 1994) |
| "The aim of this study was to demonstrate metabolic changes in the small joints of the hand due to rheumatoid arthritis by means of 31-phosphorus spectroscopy." | 3.69 | [Rheumatoid arthritis of the hand. The initial results with 31-phosphorus MR spectroscopy]. ( Bollow, M; Braun, J; König, H; Schilling, A; Wacker, F; Wolf, KJ, 1994) |
| "To investigate the effects of tenidap, a new antirheumatic drug, sodium diclofenac, a non-steroidal antiinflammatory drug, and a disease modifying antirheumatic drug, hydroxychloroquine, on the level and expression of interleukin 1 receptors (IL-1R) on synovial fibroblasts from patients with osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.69 | Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts. ( Fernandes, JC; Loose, L; Martel-Pelletier, J; Mineau, F; Pelletier, JP; Ranger, P; Tardif, G, 1996) |
| "Effects of the nonsteroidal anti-inflammatory drug, diclofenac, on stimulated monocyte superoxide production were assessed directly in vitro and following treatment of patients with rheumatoid arthritis ex vivo." | 3.68 | Diclofenac inhibits monocyte superoxide production ex vivo in rheumatoid arthritis. ( Adamson, H; Bell, AL; Kirk, F; McCaigue, MD; Rotman, H, 1991) |
| "Pharmacokinetic data for diclofenac sodium has been well established in healthy volunteers, whereas in patients with rheumatoid arthritis very little information is available in the literature." | 3.66 | The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease. ( Crook, PR; Fowler, PD; Jack, DB; Kendall, MJ; Willis, JV, 1982) |
| "Ninety patients with active rheumatoid arthritis took part in a cross-over trial comparing diclofenac sodium, diflunisal and naproxen." | 3.66 | Diclofenac sodium, diflunisal and naproxen: patient preferences for anti-inflammatory drugs in rheumatoid arthritis. ( Dieppe, PA; Huskisson, EC; Jones, H; Scott, J, 1982) |
| "The development of membranous glomerulonephritis in a 51 year old patient suffering from rheumatoid arthritis suggested drug toxicity, and particularly of a recently developed anti-inflammatory agent, diclofenac." | 3.66 | [Membranous glomerulonephritis during rheumatoid arthritis. Probable toxicity of diclofenac (author's transl)]. ( Ducret, F; Pichot, C; Pointet, P, 1980) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)." | 2.78 | Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. ( Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013) |
| " The steady-state pharmacokinetics of lumiracoxib were evaluated in plasma and synovial fluid by both a population pharmacokinetic model and noncompartmental analysis." | 2.71 | Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ( Huff, JP; Kalbag, J; Looby, M; Milosavljev, S; Reynolds, C; Rordorf, C; Ruff, DA; Scott, G; Weaver, M, 2004) |
| " Prespecified gastrointestinal adverse events were more frequent with naproxen than with either lumiracoxib dose or placebo." | 2.71 | Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. ( Alten, R; Geusens, P; Kralidis, G; Krammer, G; Richardson, P; Rovensky, J; Sloan, VS, 2004) |
| "Diclofenac 150 mg was superior to placebo for 4 of 5 primary efficacy measures (all but swollen joint count; p < 0." | 2.70 | Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. ( Fleischmann, R; Furst, DE; Greenwald, M; Hall, DB; Kolba, KS; Roszko, PJ; Roth, S; Silverfield, J, 2002) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Tenidap is a novel anti-rheumatic drug that combines cytokine modulation with cyclo-oxygenase inhibition." | 2.68 | A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. ( Appelboom, T; Bolten, W; Breedveld, FC; Feely, J; Le Loët, X; Leeming, MR; Manthorpe, R; Marcolongo, R; Smolen, J; Wylie, G, 1995) |
| " Adverse events in both groups were minor, predominantly gastro-intestinal, and fewer patients tended to experience gastro-intestinal events on aceclofenac (13%) than on diclofenac (17%)." | 2.68 | A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. ( Ferrer, F; Marcolongo, R; Parnham, MJ; Pasero, G; Serni, U, 1995) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " The employment of a special diet favourably influenced the course of the disease and enabled the dosage of antirheumatic drugs to be reduced, thereby reducing the frequency of side-effects of the drugs." | 2.67 | On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis. ( Denissov, LN; Samsonov, MA; Sharafetdinov, Kh, 1992) |
| "Plasma and knee joint synovial fluid (SF) concentration of diclofenac sodium and its hydroxylated metabolites were measured after chronic dosing with the 100 mg polymer matrix formulation." | 2.66 | Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. ( Dawes, PT; Fowler, PD; John, VA; Shotton, PA, 1986) |
| " For this the dosage of diclofenac was reduced to 100 mg/d." | 2.65 | Diclofenac and piroxicam in a double-blind trial results and methodological problems. Working Party of the Society for Rheumatology of the GDR for the Testing of Anti-rheumatic Drugs. ( Friedländer, R; Häntzschel, H; Hüge, W; Keitel, W; Keysser, M; Seidel, W; Tanner, E; Wächter, G; Weber, J; Wille, R, 1984) |
| "Diclofenac was detected in synovial fluid 2 h after dosing but at a lower level than in plasma." | 2.65 | Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. ( Crook, PR; Fowler, PD; John, VA; Shadforth, MF, 1983) |
| "Diclofenac 25 mg q." | 2.65 | Diclofenac in rheumatoid disease. ( Treadwell, BL; Tweed, JM, 1979) |
| "Diclofenac was at least as effective as equivalent doses of indomethacin and naproxen and, when treatment lasts more than 3 months, may be more effective." | 2.65 | The value and results of long-term studies with diclofenac sodium (Voltarol). ( Chaudri, HA; Ciccolunghi, SN; Schubiger, BI, 1979) |
| " Clinical parameters showed that the best degree of improvement was obtained with the diclofenac 50 mg twice-daily dosage regime." | 2.65 | Comparative clinical trials with diclofenac sodium (Voltarol) and naproxen in rheumatic conditions: investigation of possible changes in diclofenac dose and dose interval. ( Bach, GL, 1979) |
| " Dosage was one tablet (25 mg diclofenac) three times daily during the first week." | 2.65 | Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial. ( Boardman, PL; Doreen, MS; Fowler, PD; Poole, PH, 1979) |
| "and naproxen 250 mg b." | 2.64 | Diclofenac sodium (Voltaren) and naproxen in the treatment of rheumatoid arthritis: a comparative double-blind study. ( Kajander, A; Martio, J, 1978) |
| " Traditional NSAIDs are associated with an increased risk of serious gastrointestinal (GI) adverse events versus COX-2 selective inhibitors, and chronic use frequently necessitates adjunctive therapy with gastroprotective agents." | 2.44 | Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. ( Baraf, HS, 2007) |
| "Pain is a common symptom experienced by people with osteoarthritis and rheumatoid arthritis and impacts upon mobility and quality of life." | 2.44 | Pain relief in osteoarthritis and rheumatoid arthritis: TENS. ( While, A; Ying, KN, 2007) |
| " Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)." | 2.44 | Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008) |
| " Lumiracoxib has good oral bioavailability (74%)." | 2.43 | Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ( Choi, L; Mangold, JB; Marshall, P; Rordorf, CM, 2005) |
| "Diclofenac was as effective as indomethacin or sulindac in treating ankylosing spondylitis." | 2.38 | Diclofenac sodium. ( Small, RE, 1989) |
| " Adverse events of therapy were mild." | 1.56 | [Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis]. ( Akhverdyan, YR; Papichev, EV; Polyakova, YV; Sivordova, LE; Zavodovsky, BV, 2020) |
| "Valdecoxib has highest similarity to analogs 8, 19, 21, 22, 23, 26, 27, and 28." | 1.40 | Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization. ( Bartzatt, R, 2014) |
| " Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk." | 1.39 | Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. ( Simon, LS, 2013) |
| "Overview of three dose-response studies demonstrating the efficacy of lumiracoxib, a novel COX-2 selective inhibitor, for chronic pain associated with osteoarthritis (0A), or rheumatoid arthritis (RA) and acute pain following dental extraction." | 1.33 | Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. ( Gitton, X; Jayawardene, S; Schnitzer, TJ; Sloan, VS, 2005) |
| "Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors." | 1.31 | [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001) |
| "Aceclofenac was also converted into diclofenac and 4'-hydroxy diclofenac by human polymorphonuclear leukocytes and monocytes." | 1.30 | Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. ( Hashimoto, S; Kaneda, N; Kawai, S; Koshino, T; Matsuzaki, T; Mizushima, Y; Okamoto, R; Yamazaki, R; Yokokura, T, 1997) |
| "A patient with rheumatoid arthritis is described who presented with low-grade fever for 3 months, in whom Actinobacillus ureae was cultured from bone marrow aspirate." | 1.30 | Bone marrow infection caused by Actinobacillus ureae in a rheumatoid arthritis patient. ( Avlami, A; Dounis, E; Kordossis, T; Papalambrou, C; Tzivra, M, 1997) |
| " An overestimation of rare side-effects of drugs should not block the application of certain medicaments, however, they should be given only in such a high dosage as it is necessary." | 1.26 | [Hematotoxic lesions caused by non-steroidal antirheumatic agents]. ( Hüge, W; Stobbe, H, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 113 (37.17) | 18.7374 |
| 1990's | 77 (25.33) | 18.2507 |
| 2000's | 70 (23.03) | 29.6817 |
| 2010's | 36 (11.84) | 24.3611 |
| 2020's | 8 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Akgul, O | 1 |
| Di Cesare Mannelli, L | 2 |
| Vullo, D | 1 |
| Angeli, A | 1 |
| Ghelardini, C | 2 |
| Bartolucci, G | 2 |
| Alfawaz Altamimi, AS | 1 |
| Scozzafava, A | 1 |
| Supuran, CT | 2 |
| Carta, F | 2 |
| Bua, S | 1 |
| Lucarini, L | 1 |
| Micheli, L | 1 |
| Menicatti, M | 1 |
| Selleri, S | 1 |
| Masini, E | 1 |
| Gratteri, P | 1 |
| Nocentini, A | 1 |
| Omidian, S | 1 |
| Aghazadeh, Z | 2 |
| Ahmadzadeh, A | 2 |
| Aslani, M | 2 |
| Hosseini, M | 2 |
| Abbasi, S | 2 |
| Mirshafiey, A | 2 |
| Sharanya, CS | 1 |
| Abhithaj, J | 1 |
| Arun, KG | 1 |
| Eeda, KR | 1 |
| Bhat, V | 1 |
| Variyar, EJ | 1 |
| Sabu, A | 1 |
| Haridas, M | 1 |
| Zaki-Dizaji, M | 1 |
| Sharifi, L | 1 |
| Zavodovsky, BV | 1 |
| Sivordova, LE | 1 |
| Polyakova, YV | 1 |
| Akhverdyan, YR | 1 |
| Papichev, EV | 1 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 1 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 6 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 3 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 2 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 4 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 3 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 5 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Liu, J | 2 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 2 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 2 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 4 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 4 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Jurca, T | 1 |
| Józsa, L | 1 |
| Suciu, R | 1 |
| Pallag, A | 1 |
| Marian, E | 1 |
| Bácskay, I | 1 |
| Mureșan, M | 1 |
| Stan, RL | 1 |
| Cevei, M | 1 |
| Cioară, F | 1 |
| Vicaș, L | 1 |
| Fehér, P | 1 |
| Gad, SS | 1 |
| Fayez, AM | 1 |
| Abdelaziz, M | 1 |
| Abou El-Ezz, D | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Kalso, EA | 1 |
| Bell, RF | 1 |
| Aldington, D | 1 |
| Phillips, T | 1 |
| Gaskell, H | 1 |
| Moore, RA | 2 |
| Poorvashree, J | 1 |
| Suneela, D | 1 |
| Kopylov, AT | 1 |
| Novikov, AA | 1 |
| Kaysheva, AL | 1 |
| Vykhodets, IT | 1 |
| Karateev, DE | 1 |
| Zgoda, VG | 1 |
| Lisitsa, AV | 1 |
| Tian, M | 1 |
| Zhang, W | 1 |
| Mei, H | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Manappallil, RG | 1 |
| Prasan, D | 1 |
| Peringat, J | 1 |
| Biju, IK | 1 |
| Kisukeda, T | 1 |
| Onaya, J | 1 |
| Yoshioka, K | 1 |
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 1 |
| Ramasamy, T | 1 |
| Ruttala, HB | 1 |
| Umadevi, SK | 1 |
| Bartzatt, R | 1 |
| Simon, LS | 2 |
| Inoue, T | 2 |
| Iijima, H | 1 |
| Arimitsu, J | 1 |
| Hagihara, K | 1 |
| Kawai, S | 4 |
| Shiraishi, E | 1 |
| Hiyama, S | 1 |
| Mukai, A | 1 |
| Shinzaki, S | 1 |
| Nishida, T | 1 |
| Ogata, A | 1 |
| Tsujii, M | 1 |
| Takehara, T | 1 |
| Arushanian, ÉB | 1 |
| Naumov, SS | 1 |
| Ivanova, VN | 1 |
| Lomonosova, KV | 1 |
| Spies, CM | 1 |
| Stemmler, E | 1 |
| Buttgereit, F | 1 |
| van Walsem, A | 1 |
| Pandhi, S | 1 |
| Nixon, RM | 1 |
| Guyot, P | 1 |
| Karabis, A | 1 |
| Scherneck, S | 1 |
| Schöpa, FL | 1 |
| Entezami, M | 1 |
| Kayser, A | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Sanka, K | 1 |
| Pragada, RR | 1 |
| Veerareddy, PR | 1 |
| Liao, AH | 2 |
| Chuang, HC | 1 |
| Chung, HY | 2 |
| Akramas, L | 1 |
| Leonavičienė, L | 1 |
| Vasiliauskas, A | 1 |
| Bradūnaitė, R | 1 |
| Vaitkienė, D | 1 |
| Zabulytė, D | 1 |
| Normantienė, T | 1 |
| Lukošius, A | 1 |
| Jonauskienė, I | 1 |
| Chen, WS | 1 |
| Yeh, MK | 1 |
| Sharma, G | 1 |
| Saini, MK | 1 |
| Thakur, K | 1 |
| Kapil, N | 1 |
| Garg, NK | 1 |
| Raza, K | 1 |
| Goni, VG | 1 |
| Pareek, A | 1 |
| Katare, OP | 1 |
| He, Y | 3 |
| Lu, A | 3 |
| Zha, Y | 2 |
| Tsang, I | 1 |
| Rozin, AP | 1 |
| Braun-Moscovici, Y | 1 |
| Balbir-Gurman, A | 1 |
| Laine, L | 6 |
| Goldkind, L | 1 |
| Curtis, SP | 7 |
| Connors, LG | 1 |
| Yanqiong, Z | 1 |
| Cannon, CP | 6 |
| Krum, H | 2 |
| Swergold, G | 1 |
| Kaur, A | 5 |
| Smugar, SS | 1 |
| Weir, MR | 1 |
| Brater, DC | 1 |
| Sizova, LV | 1 |
| Bagirova, GG | 1 |
| Chernysheva, TV | 1 |
| Jiang, M | 1 |
| Zhao, J | 1 |
| Zha, Q | 1 |
| Inotai, A | 1 |
| Rojkovich, B | 1 |
| Mészáros, A | 1 |
| Villalonga, N | 1 |
| David, M | 1 |
| Bielańska, J | 1 |
| González, T | 1 |
| Parra, D | 1 |
| Soler, C | 1 |
| Comes, N | 1 |
| Valenzuela, C | 1 |
| Felipe, A | 1 |
| Cheung, R | 1 |
| Cheng, TT | 1 |
| Lin, HY | 1 |
| Lai, K | 1 |
| Lau, CS | 1 |
| Feng, H | 1 |
| Parsons, B | 1 |
| Rahme, E | 1 |
| Bernatsky, S | 1 |
| Chan, FK | 2 |
| Lanas, A | 2 |
| Scheiman, J | 1 |
| Berger, MF | 2 |
| Nguyen, H | 2 |
| Goldstein, JL | 5 |
| Alekseeva, LI | 1 |
| Böttcher, A | 1 |
| Guder, E | 1 |
| Just, T | 1 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Brune, K | 1 |
| Gatica, H | 1 |
| Aliste, M | 1 |
| Guerrero, J | 1 |
| Goecke, IA | 1 |
| Wilcox, CM | 1 |
| Peura, D | 1 |
| Sands, GH | 1 |
| Scheiman, JM | 1 |
| Abdulganieva, DI | 1 |
| Belianskaia, NE | 1 |
| Chandran, B | 1 |
| Goel, A | 1 |
| Setoguchi, N | 1 |
| Takamura, N | 2 |
| Fujita, K | 2 |
| Tokunaga, J | 2 |
| Nishio, T | 1 |
| Chosa, E | 2 |
| Arimori, K | 2 |
| Kawai, K | 2 |
| Yamamoto, R | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Andersson, T | 1 |
| Frösing, R | 1 |
| Li, YN | 1 |
| Zhao, YS | 1 |
| Pavelka, K | 6 |
| Recker, DP | 1 |
| Verburg, KM | 3 |
| von Scheele, B | 1 |
| Peña, B | 1 |
| Wong, J | 1 |
| Niculescu, L | 1 |
| Burian, M | 1 |
| Geisslinger, G | 1 |
| Zuber-Jerger, I | 1 |
| Drexel, H | 1 |
| Shi, W | 2 |
| Wang, YM | 2 |
| Cheng, NN | 2 |
| Chen, BY | 2 |
| Li, D | 2 |
| Li, SL | 1 |
| Yan, M | 1 |
| Scott, G | 1 |
| Rordorf, C | 1 |
| Reynolds, C | 1 |
| Kalbag, J | 1 |
| Looby, M | 1 |
| Milosavljev, S | 2 |
| Weaver, M | 1 |
| Huff, JP | 1 |
| Ruff, DA | 1 |
| Kivitz, AJ | 1 |
| Nayiager, S | 1 |
| Schimansky, T | 1 |
| Gimona, A | 1 |
| Thurston, HJ | 1 |
| Hawkey, C | 1 |
| Legrand, E | 1 |
| Hartmann, SN | 1 |
| Rordorf, CM | 2 |
| Branson, JM | 1 |
| Chales, GH | 1 |
| Juvin, RR | 1 |
| Lafforgue, P | 1 |
| Le Parc, JM | 1 |
| Tavernier, CG | 1 |
| Meyer, OC | 1 |
| Lyseng-Williamson, KA | 1 |
| Curran, MP | 1 |
| Biegert, C | 1 |
| Wagner, I | 1 |
| Lüdtke, R | 1 |
| Kötter, I | 1 |
| Lohmüller, C | 1 |
| Günaydin, I | 1 |
| Taxis, K | 1 |
| Heide, L | 1 |
| Geusens, P | 1 |
| Alten, R | 2 |
| Rovensky, J | 1 |
| Sloan, VS | 3 |
| Krammer, G | 2 |
| Kralidis, G | 1 |
| Richardson, P | 1 |
| Ablassmaier, B | 1 |
| Hartmann, J | 1 |
| Doggrell, SA | 1 |
| Rabeneck, L | 1 |
| Vu, A | 1 |
| Mayne, TJ | 1 |
| Rublee, DA | 1 |
| Dugina, JL | 1 |
| Petrov, VI | 1 |
| Babayeva, AR | 1 |
| Martyushev-Poklad, AV | 1 |
| Tcherevkova, EV | 1 |
| Epstein, OI | 1 |
| Sergeeva, SA | 1 |
| Schnitzer, TJ | 1 |
| Gitton, X | 3 |
| Jayawardene, S | 1 |
| Bannwarth, B | 1 |
| Berenbaum, F | 1 |
| Türker, S | 2 |
| Erdoğan, S | 2 |
| Ozer, AY | 1 |
| Ergün, EL | 1 |
| Tuncel, M | 1 |
| Bilgili, H | 2 |
| Deveci, S | 2 |
| Kumar, VS | 1 |
| Kumar, DA | 1 |
| Kalaivani, K | 1 |
| Gangadharan, AC | 1 |
| Raju, KV | 1 |
| Thejomoorthy, P | 1 |
| Manohar, BM | 1 |
| Puvanakrishnan, R | 1 |
| Hochberg, MC | 1 |
| Matchaba, P | 1 |
| Ehrsam, E | 1 |
| Olson, M | 1 |
| Mellein, B | 1 |
| Hoexter, G | 2 |
| Orloff, J | 1 |
| Garaud, JJ | 1 |
| Choi, L | 1 |
| Marshall, P | 1 |
| Mangold, JB | 1 |
| Hawkey, CJ | 1 |
| Richard, D | 1 |
| Weinstein, WM | 1 |
| Sari, I | 1 |
| Akar, S | 1 |
| Birlik, M | 1 |
| Sis, B | 1 |
| Onen, F | 1 |
| Akkoc, N | 1 |
| Bolognese, JA | 3 |
| Whelton, A | 2 |
| Lefkowith, JL | 1 |
| West, CR | 1 |
| FitzGerald, GA | 1 |
| Reicin, AS | 2 |
| Bombardier, C | 2 |
| Weinblatt, ME | 1 |
| van der Heijde, D | 1 |
| Erdmann, E | 1 |
| Zha, QL | 1 |
| He, YT | 1 |
| Yan, XP | 1 |
| Su, L | 2 |
| Song, YJ | 1 |
| Zeng, SP | 1 |
| Feng, XH | 1 |
| Qian, X | 2 |
| Zhu, WH | 1 |
| Lin, SQ | 1 |
| Lü, AP | 1 |
| Ko, AT | 1 |
| Cavanaugh, PF | 1 |
| Cryer, B | 1 |
| Mythilypriya, R | 1 |
| Shanthi, P | 1 |
| Sachdanandam, P | 1 |
| Einecke, D | 2 |
| Krüger, K | 2 |
| Baraf, HS | 1 |
| Zhang, JH | 1 |
| Wang, JP | 1 |
| Wang, HJ | 1 |
| Ying, KN | 1 |
| While, A | 1 |
| Krueger, K | 1 |
| Lino, L | 1 |
| Dore, R | 1 |
| Radominski, S | 1 |
| Simpson, R | 1 |
| Curtis, S | 1 |
| Shi, S | 1 |
| Klotz, U | 1 |
| Ozer, YA | 1 |
| Song, Y | 1 |
| Zeng, S | 1 |
| Zhu, W | 1 |
| Rohde, J | 1 |
| Schwegler, F | 1 |
| Standel, W | 1 |
| Gabrielsen, TO | 1 |
| Staerfelt, F | 1 |
| Thune, PO | 1 |
| Baroni, L | 2 |
| Borghi, C | 1 |
| Trombetta, N | 3 |
| Małdykowa, H | 1 |
| Abgarowicz-Miłkowska, T | 1 |
| Dratwianka, B | 1 |
| Grabowska, A | 1 |
| Jedryka, A | 1 |
| Bedi, SS | 1 |
| Eberl, R | 2 |
| Million, R | 1 |
| Silas, AM | 1 |
| Wafin, F | 1 |
| Valindas, E | 1 |
| Wuolijoki, E | 1 |
| Al-Sharkawi, MS | 1 |
| Schichikawa, K | 1 |
| Ichikawa, Y | 1 |
| Ogawa, N | 1 |
| Keitel, W | 1 |
| Friedländer, R | 1 |
| Häntzschel, H | 2 |
| Hüge, W | 2 |
| Keysser, M | 1 |
| Seidel, W | 1 |
| Tanner, E | 2 |
| Wächter, G | 2 |
| Weber, J | 1 |
| Wille, R | 1 |
| Grosse-Kielisch, C | 1 |
| Bach, GL | 3 |
| Guobis, G | 1 |
| Iushenaite, Ia | 1 |
| Hurault de Ligny, B | 1 |
| Faure, G | 1 |
| Béné, MC | 1 |
| Kessler, M | 1 |
| Huriet, C | 1 |
| Szczepański, L | 1 |
| Kowalewski, J | 1 |
| Miturzyńska-Stryjecka, H | 1 |
| Horubała-Bielak, G | 1 |
| Fowler, PD | 9 |
| Shadforth, MF | 1 |
| Crook, PR | 3 |
| John, VA | 2 |
| Isomäki, H | 2 |
| Martio, J | 2 |
| Kaarela, K | 1 |
| Kajander, A | 2 |
| Koota, K | 1 |
| Lehtinen, K | 1 |
| Luukkainen, R | 1 |
| Martio, T | 1 |
| Nissilä, M | 2 |
| Nuotio, P | 2 |
| Vojtísek, O | 3 |
| Malecek, J | 1 |
| Kanková, D | 2 |
| Schlumpf, U | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Pakes, GE | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Brooks, PM | 1 |
| Hill, W | 1 |
| Geddes, R | 1 |
| Sigidin, IaA | 5 |
| Tsvetkova, ES | 7 |
| Bunchuk, NV | 2 |
| Murav'ev, IuV | 2 |
| Loos-Vranić, V | 1 |
| Meinicke, J | 1 |
| Danneskiold-Samsøe, B | 1 |
| Caruso, I | 2 |
| De Candia, O | 2 |
| Frizziero, L | 2 |
| Loizzi, P | 1 |
| Mattara, L | 1 |
| Riente, L | 1 |
| Cornelli, U | 3 |
| Hothersall, TE | 1 |
| Lasarof, I | 1 |
| Gaida, P | 1 |
| Comoglio, T | 1 |
| Willis, JV | 1 |
| Kendall, MJ | 1 |
| Jack, DB | 1 |
| Huskisson, EC | 3 |
| Dieppe, PA | 1 |
| Scott, J | 1 |
| Jones, H | 1 |
| Chiswell, RJ | 2 |
| Seldrup, J | 1 |
| Ducret, F | 2 |
| Pointet, P | 2 |
| Pichot, C | 2 |
| Tympner, F | 1 |
| Vetter, G | 1 |
| Abele, I | 1 |
| Grieve, AP | 1 |
| MacDonald, IR | 1 |
| Stobbe, H | 1 |
| Lacki, JK | 3 |
| Mackiewicz, SH | 3 |
| Wiktorowicz, KE | 2 |
| Wylie, G | 1 |
| Appelboom, T | 1 |
| Bolten, W | 1 |
| Breedveld, FC | 2 |
| Feely, J | 1 |
| Leeming, MR | 1 |
| Le Loët, X | 1 |
| Manthorpe, R | 1 |
| Marcolongo, R | 3 |
| Smolen, J | 1 |
| Kremer, JM | 2 |
| Lawrence, DA | 1 |
| Petrillo, GF | 1 |
| Litts, LL | 1 |
| Mullaly, PM | 1 |
| Rynes, RI | 1 |
| Stocker, RP | 1 |
| Parhami, N | 1 |
| Greenstein, NS | 1 |
| Fuchs, BR | 1 |
| Downie, WW | 2 |
| Gagnier, P | 1 |
| D'Alteroche, L | 1 |
| Bourlier, P | 1 |
| Barre, I | 1 |
| Metman, EH | 1 |
| Agrawal, NM | 2 |
| Van Kerckhove, HE | 1 |
| Erhardt, LJ | 1 |
| Geis, GS | 6 |
| Bacon, PA | 1 |
| de Queiroz, MV | 1 |
| Beaulieu, A | 1 |
| Woods, E | 1 |
| Stead, H | 3 |
| Geis, S | 1 |
| Peloso, PM | 1 |
| Goldsmith, CH | 1 |
| Ardia, A | 1 |
| Franchini, S | 1 |
| Baggio, A | 1 |
| Owen, SG | 1 |
| Francis, HW | 1 |
| Roberts, MS | 1 |
| Alekberova, ZS | 1 |
| Balabanova, RM | 2 |
| Ivanova, MM | 1 |
| Chichasova, NV | 1 |
| Nasonov, EL | 1 |
| Dormidontov, EN | 1 |
| Korshunov, NI | 1 |
| Baranova, EIa | 1 |
| Parusova, NI | 1 |
| Ial'tseva, NV | 1 |
| Savel'eva, MI | 1 |
| Kurowski, M | 2 |
| Menninger, H | 1 |
| Pauli, E | 1 |
| Wacker, F | 1 |
| Schilling, A | 1 |
| Braun, J | 1 |
| Bollow, M | 1 |
| König, H | 1 |
| Wolf, KJ | 1 |
| Galeazzi, M | 1 |
| Wittenberg, RH | 1 |
| Willburger, RE | 1 |
| Kleemeyer, KS | 1 |
| Peskar, BA | 1 |
| Bianchi Porro, G | 2 |
| Montrone, F | 2 |
| Petrillo, M | 2 |
| Ardizzone, S | 2 |
| Lonauer, G | 1 |
| Tisscher, JR | 1 |
| Lim, HG | 1 |
| Bijlsma, JW | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 3 |
| DeLapp, RE | 3 |
| Jensen, CP | 1 |
| Morgan, GJ | 1 |
| Lister, BJ | 1 |
| Furst, DE | 2 |
| Anderson, W | 1 |
| Martín-Mola, E | 1 |
| Gijón-Baños, J | 1 |
| Ansoleaga, JJ | 2 |
| Sacerdote, P | 1 |
| Carrabba, M | 1 |
| Galante, A | 1 |
| Pisati, R | 1 |
| Manfredi, B | 1 |
| Panerai, AE | 1 |
| Swaak, AJ | 1 |
| Kornasoff, D | 1 |
| Maisenbacher, J | 1 |
| Bowdler, J | 1 |
| Raber, A | 1 |
| Pasero, G | 1 |
| Serni, U | 1 |
| Parnham, MJ | 2 |
| Ferrer, F | 1 |
| Martel-Pelletier, J | 1 |
| Mineau, F | 1 |
| Tardif, G | 1 |
| Fernandes, JC | 1 |
| Ranger, P | 1 |
| Loose, L | 1 |
| Pelletier, JP | 1 |
| Hunter, JA | 1 |
| Balaguer, XG | 1 |
| Perez-Ruiz, F | 1 |
| Alonso-Ruiz, A | 1 |
| Miglioli, M | 1 |
| Vaira, D | 1 |
| Menegatti, M | 1 |
| Brunetti, G | 1 |
| Grandinetti, G | 1 |
| Kovarik, JM | 1 |
| Kurki, P | 1 |
| Mueller, E | 1 |
| Guerret, M | 1 |
| Markert, E | 1 |
| Zeidler, H | 1 |
| Genth-Stolzenburg, S | 1 |
| Yamazaki, R | 3 |
| Matsuzaki, T | 3 |
| Kaneda, N | 1 |
| Hashimoto, S | 3 |
| Yokokura, T | 3 |
| Okamoto, R | 2 |
| Koshino, T | 2 |
| Mizushima, Y | 4 |
| Takahashi, S | 1 |
| Higaki, M | 1 |
| Avlami, A | 1 |
| Papalambrou, C | 1 |
| Tzivra, M | 1 |
| Dounis, E | 1 |
| Kordossis, T | 1 |
| Walker, DJ | 1 |
| Heslop, P | 1 |
| Chandler, C | 1 |
| McKenna, F | 1 |
| Rau, R | 1 |
| Wittenborg, A | 1 |
| Petersen, G | 1 |
| Lorkowski, G | 1 |
| Brabant, T | 1 |
| Lecoules, S | 1 |
| Duvic, C | 1 |
| Hérody, M | 1 |
| Nédélec, G | 1 |
| Al, MJ | 1 |
| Michel, BC | 1 |
| Rutten, FF | 1 |
| Matsumoto, T | 1 |
| Constantopoulos, A | 1 |
| Morgan, D | 1 |
| Llenas, J | 1 |
| Jokhio, IA | 1 |
| Siddiqui, KA | 1 |
| Waraich, T | 1 |
| Abbas, M | 1 |
| Ali, A | 1 |
| Kristiansen, IS | 1 |
| Kvien, TK | 1 |
| Nord, E | 1 |
| Mihai, R | 1 |
| Dixon, JH | 1 |
| Klein, G | 1 |
| Kullich, W | 1 |
| Iakushin, SS | 1 |
| Filonenko, SP | 1 |
| Dediunina, RS | 1 |
| Lukina, IM | 1 |
| Ito, A | 1 |
| Stanislavchuk, MA | 1 |
| Kosinski, M | 1 |
| Zhao, SZ | 1 |
| Dedhiya, S | 1 |
| Osterhaus, JT | 1 |
| Ware, JE | 1 |
| Mendonça, LL | 1 |
| Khamashta, MA | 1 |
| Nelson-Piercy, C | 1 |
| Hunt, BJ | 1 |
| Hughes, GR | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Pincus, T | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Zhao, WW | 1 |
| Kent, JD | 1 |
| Lefkowith, JB | 1 |
| Soto Alvarez, J | 1 |
| Alekseeva, AV | 1 |
| Tive, L | 1 |
| Reginster, JY | 1 |
| Paul, I | 1 |
| Henrotin, Y | 1 |
| Peris, F | 1 |
| Martínez, E | 1 |
| Badia, X | 1 |
| Brosa, M | 1 |
| Deray, G | 1 |
| Kolba, KS | 1 |
| Fleischmann, R | 1 |
| Silverfield, J | 1 |
| Greenwald, M | 1 |
| Roth, S | 1 |
| Hall, DB | 1 |
| Roszko, PJ | 1 |
| Eisen, GM | 1 |
| Burke, TA | 1 |
| Peña, BM | 1 |
| Lefkowith, J | 1 |
| Menassé, R | 1 |
| Hedwall, PR | 1 |
| Kraetz, J | 1 |
| Pericin, C | 1 |
| Riesterer, L | 1 |
| Sallmann, A | 1 |
| Ziel, R | 1 |
| Jaques, R | 1 |
| Ciucci, AG | 1 |
| Dürrigl, T | 1 |
| Vitaus, M | 1 |
| Pucar, I | 1 |
| Miko, M | 1 |
| Miura, T | 1 |
| Michot, F | 1 |
| Ajdacic, K | 1 |
| Glaus, L | 1 |
| Pappalardo, A | 1 |
| Pulizzi, C | 1 |
| Mantia, S | 1 |
| Trofimova, TM | 1 |
| Nicoletti, B | 1 |
| Mignemi, G | 1 |
| Usobiaga Marchal, JL | 1 |
| Durante, F | 1 |
| López-Prats Dasi, JL | 1 |
| Menchón Galiana, M | 1 |
| López Prats, JL | 1 |
| Doreen, MS | 2 |
| Boardman, PL | 2 |
| Poole, PH | 2 |
| Abrams, GJ | 1 |
| Solomon, L | 1 |
| Meyers, OL | 1 |
| Bijlsma, A | 2 |
| ten Pas, JG | 1 |
| Mutru, O | 1 |
| Penttilä, M | 1 |
| Pesonen, J | 1 |
| Salmela, P | 1 |
| Suhonen, O | 1 |
| Sonck, T | 1 |
| Fomina, AA | 1 |
| Mironova, KA | 1 |
| Klimovich, MD | 1 |
| Baghiris, D | 1 |
| Pemberton, RE | 1 |
| Strand, LJ | 1 |
| Treadwell, BL | 1 |
| Tweed, JM | 1 |
| Rejholec, V | 1 |
| Vapaatalo, H | 2 |
| Tokola, O | 1 |
| Gothoni, G | 1 |
| Ciccolunghi, SN | 3 |
| Chaudri, HA | 2 |
| Schubiger, BI | 3 |
| Bogdanikowa, B | 1 |
| Stasiewicz, A | 1 |
| Barnes, CG | 1 |
| Berry, H | 1 |
| Carter, ME | 1 |
| Moll, JM | 1 |
| Perry, JD | 1 |
| Sawaf, MS | 1 |
| Wright, V | 2 |
| Bonomo, I | 1 |
| McMahon, MF | 1 |
| Cash, HC | 1 |
| Cardoe, N | 1 |
| Reddrop, R | 1 |
| Bremová, A | 1 |
| Dostál, C | 1 |
| Králová, M | 1 |
| Terruzzi, V | 1 |
| Minoli, G | 1 |
| Tausch, G | 1 |
| Tuschl, P | 1 |
| Scott, DL | 1 |
| de Melo Gomes, JA | 1 |
| Hannequin, JR | 1 |
| Dunky, A | 1 |
| Denissov, LN | 1 |
| Sharafetdinov, Kh | 1 |
| Samsonov, MA | 1 |
| Verdickt, W | 1 |
| Moran, C | 1 |
| Fraga, AM | 1 |
| Adebajo, AO | 1 |
| Eastmond, CJ | 1 |
| Bell, AL | 1 |
| Adamson, H | 1 |
| Kirk, F | 1 |
| McCaigue, MD | 1 |
| Rotman, H | 1 |
| Branthwaite, JP | 1 |
| Nicholls, A | 1 |
| Ghosh, P | 1 |
| Wells, C | 1 |
| Smith, M | 1 |
| Hutadilok, N | 1 |
| Bondeson, J | 1 |
| Berglund, S | 1 |
| Boers, M | 1 |
| Dijkmans, BA | 2 |
| Camps, JA | 1 |
| Chang, PC | 1 |
| Van Brummelen, P | 1 |
| Pauwels, EK | 1 |
| Cats, A | 1 |
| Wallemark, CB | 1 |
| Nicholson, PA | 1 |
| Wijnands, M | 1 |
| van Riel, P | 1 |
| van 't Hof, M | 1 |
| Gribnau, F | 1 |
| van de Putte, L | 1 |
| Veenendaal, RA | 1 |
| Peeters, AJ | 1 |
| Kreuning, J | 1 |
| Peña, S | 1 |
| Gooszen, HG | 1 |
| Lamers, CB | 1 |
| Bassam, B | 1 |
| Helfgott, SM | 1 |
| Sandberg-Cook, J | 1 |
| Zakim, D | 1 |
| Nestler, J | 1 |
| Crowley, B | 1 |
| Hamill, JJ | 1 |
| Lyndon, S | 1 |
| McKellican, JF | 1 |
| Williams, P | 1 |
| Miller, AJ | 1 |
| Schlichter, A | 1 |
| Brundig, P | 2 |
| Dimitrakov, D | 1 |
| Pavlova, M | 1 |
| Natov, S | 1 |
| Simeonov, S | 1 |
| Trnavsky, K | 1 |
| Briancon, D | 1 |
| Karbowski, A | 1 |
| Ciompi, ML | 1 |
| Puccetti, L | 1 |
| Bazzichi, L | 1 |
| Remorini, E | 1 |
| Marotta, G | 1 |
| Kazis, LE | 1 |
| Anderson, JJ | 2 |
| Meenan, RF | 2 |
| Firschein, HE | 1 |
| Small, RE | 1 |
| Zhukovskaia, GN | 1 |
| Mikunis, RI | 1 |
| Stoliarchuk, AA | 1 |
| Stepaniuk, GI | 1 |
| Bogach, NT | 1 |
| Moilanen, E | 1 |
| Mege, JL | 1 |
| Capo, C | 1 |
| Bongrand, P | 1 |
| Richard, P | 1 |
| Roux, H | 1 |
| Kolodny, AL | 1 |
| Hambsch, K | 1 |
| Löbe, M | 1 |
| Ludewig, R | 1 |
| Müller, P | 1 |
| Herrmann, F | 1 |
| Sorger, D | 1 |
| Boey, ML | 1 |
| Rae, S | 1 |
| Feng, PH | 1 |
| Janssen, M | 1 |
| Van Leeuwen, MH | 1 |
| Albrecht, H | 1 |
| Wysocka, K | 1 |
| Regulski, M | 1 |
| Kukes, VG | 1 |
| Murashko, VV | 1 |
| Iagunina, MV | 1 |
| Volchenok, VI | 1 |
| Pokryshkin, VI | 1 |
| Cherevatov, BG | 1 |
| Shelest, AN | 1 |
| Volnenko, NB | 1 |
| Cherevatova, SKh | 1 |
| Dawes, PT | 1 |
| Shotton, PA | 1 |
| Zuckner, J | 1 |
| Caldwell, JR | 2 |
| Weisman, MH | 1 |
| Bird, HA | 1 |
| Hill, J | 1 |
| Leatham, P | 1 |
| Petersson, I | 1 |
| Nilsson, G | 1 |
| Hansson, BG | 1 |
| Hedner, T | 1 |
| Youinou, P | 1 |
| Lepoivre, B | 1 |
| Jouquan, J | 1 |
| Le Goff, P | 1 |
| Pirlich, W | 1 |
| Börner, RH | 1 |
| Wittig, E | 1 |
| Seppälä, E | 1 |
| Nykänen, E | 1 |
| Laitinen, O | 1 |
| Eberhardt, R | 1 |
| Schürmann, W | 1 |
| Liauw, HL | 1 |
| Ku, E | 1 |
| Brandt, KD | 2 |
| Benson, MD | 2 |
| Aldo-Benson, MA | 1 |
| Waiter, SL | 1 |
| Lee, W | 1 |
| Chan, K | 1 |
| Vyas, K | 1 |
| Pal, B | 1 |
| Hossain, MA | 1 |
| Zorzin, L | 1 |
| Maira, MG | 1 |
| Giobbio, A | 1 |
| Capone, M | 1 |
| Mazzullo, G | 1 |
| Calabria, AA | 1 |
| Lalumera, M | 1 |
| Fioravanti, A | 1 |
| Bacarelli, MR | 1 |
| Pucci, G | 1 |
| Renieri, A | 1 |
| Aldo-Benson, M | 1 |
| Macauley, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Evaluation of Pharmacokinetic Parameters of Diprospan"[NCT03119454] | 40 participants (Actual) | Observational [Patient Registry] | 2016-10-31 | Completed | |||
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Effect of Chronic Pain Relief Over Knee Joint Area by Gua Sha Therapy[NCT03821194] | 40 participants (Anticipated) | Interventional | 2019-01-25 | Recruiting | |||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| External Validation of a Clinical Scoring System to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea[NCT06031064] | 200 participants (Anticipated) | Observational | 2022-05-15 | Recruiting | |||
| A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150] | Phase 2 | 39 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943] | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| The Impact of Musculoskeletal Ultrasound-added to Clinical Evaluations- on Patient Reported Outcomes: A Prospective Study of Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity (ULTRAPRO)[NCT03228342] | 94 participants (Actual) | Interventional | 2017-05-03 | Completed | |||
| Effectiveness of a Psycho-educational Intervention for People With Suicidal Conduct in the Prison Environment. N'VIU Project: a Randomized Control Trial[NCT05195554] | 178 participants (Anticipated) | Interventional | 2022-01-15 | Not yet recruiting | |||
| Validation of the European Oncology Quality of Life Toolkit. A European Pilot Survey.[NCT05947903] | 4,000 participants (Anticipated) | Observational | 2024-04-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline
| Intervention | percentage of change in FMD (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 6.7 | 6.9 |
| All COPD Patients | 3.1 | 4.7 |
A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline
| Intervention | m/sec (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 11 | 10 |
| All COPD Patients | 14 | 11 |
35 reviews available for diclofenac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews.
Topics: Acute Pain; Adult; Analgesics; Arthritis, Rheumatoid; Capsaicin; Chronic Pain; Diclofenac; Humans; K | 2017 |
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofe | 2018 |
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofe | 2015 |
[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study pro
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Etoricoxib; Gastrointest | 2010 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; China; Diclofenac; Humans | 2003 |
Aceclofenac in the management of inflammatory pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 2004 |
The safety of lumiracoxib when used in the treatment of arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Org | 2005 |
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy | 2005 |
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen | 2005 |
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Ki | 2005 |
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Disea | 2006 |
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; | 2006 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Dis | 2007 |
Pain relief in osteoarthritis and rheumatoid arthritis: TENS.
Topics: Adjuvants, Immunologic; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; C | 2007 |
[Need for pharmaceutical skill in using displacement of protein binding].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Binding Sites; Blood Proteins; | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2008 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
[The introduction of non-steroidal antirheumatics: is there a rational therapy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbazoles; Chronic Disease; Diclofe | 1982 |
Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.
Topics: Adult; Animals; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Drug Interact | 1980 |
Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Combinations; Humans; Misoprostol; Oste | 1993 |
Review of the safety of diclofenac/misoprostol.
Topics: Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Humans; Misoprostol; Osteoarthritis; Safety; S | 1993 |
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Diclofenac; Humans; Osteoarthritis | 1993 |
Arthrotec: the evidence speaks for itself.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 1999 |
n-3 fatty acid supplements in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Dietary Supplem | 2000 |
[Reducing pain by oral enzyme therapy in rheumatic diseases].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bromelains; Clinical Tr | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage; Chronic Disease; Diclofen | 2001 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
Diclofenac-induced thrombocytopenic purpura with renal and hepatic involvement.
Topics: Acute Kidney Injury; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Jaundice; Middle Aged; Purpu | 1991 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Diclofenac sodium.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Humans; Osteoar | 1989 |
154 trials available for diclofenac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Formulation of Topical Dosage Forms Containing Synthetic and Natural Anti-Inflammatory Agents for the Treatment of Rheumatoid Arthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Calendula; | 2020 |
Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study.
Topics: Adult; Arthritis, Rheumatoid; Betamethasone; Diclofenac; Drug Combinations; Ethanol; Female; Glucoco | 2018 |
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |
Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Capsule Endoscopy; Celecoxib; | 2014 |
Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2008 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Cyclooxygenase | 2009 |
[Comparative analysis of effectiveness and safety of diclofenac and nimesulide in patients with early rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Fema | 2009 |
Does gastrointestinal adverse drug reaction influence therapeutic effect in the treatment of rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Drugs, Chinese H | 2010 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celeco | 2011 |
[Dynamics of intragastric acidity in patients with osteoarthritis and rheumatoid arthritis during therapy with diclofenac sodium].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Endoscopy, Gastro | 2011 |
A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Curcumin; Diclofenac; Drug Therapy, Combination; | 2012 |
A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Binding Sites; Butanones; Cyclooxygenase Inhibitors; Diclofenac; Drug M | 2013 |
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2002 |
[Study on abnormality and regulation of T-lymphocyte subsets in peripheral blood of rheumatoid arthritis patients].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; CD4-CD8 Ratio; Di | 2002 |
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclo | 2003 |
Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cohort Studies; Cost Sa | 2003 |
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Arthritis, Rheumatoid; Cyclooxygenase Inhibitor | 2004 |
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygen | 2004 |
Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Cyclooxyge | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl | 2004 |
Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheu | 2004 |
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthr | 2004 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofena | 2005 |
A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthri | 2005 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2006 |
[Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drugs, Chinese Herbal; Female; Human | 2007 |
[Clinical study on effect of total panax notoginseng saponins on immune related inner environment imbalance in rheumatoid arthritis patients].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 2007 |
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiova | 2008 |
Correlations between symptoms as assessed in traditional chinese medicine (TCM) and ACR20 efficacy response: a comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 2007 |
[Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac].
Topics: Adult; Aged; Alpha-Globulins; Arthritis, Rheumatoid; Blood Sedimentation; Diclofenac; Female; Humans | 1980 |
[Evaluation of the efficacy of a single daily administration of slow-release diclofenac in the treatment of degenerative and non-degenerative arthropathies. Multicenter study concerning 643 patients].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Administr | 1984 |
[Results of treatment of patients with rheumatoid arthritis with Voltaren SR and Metindol].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; | 1983 |
Fenclofenac and diclofenac in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Blood Viscosity; Clinical Trials as Topic; | 1984 |
Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Tolerance; Hu | 1984 |
A multicentre study of diclofenac sodium slow-release (Voltaren Retard) in the treatment of rheumatic disorders in the Kingdom of Saudi Arabia.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Diclofenac; Fem | 1984 |
[Clinical evaluation of suprofen in the treatment of rheumatoid arthritis--double-blind comparison with diclofenac sodium].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind M | 1984 |
Diclofenac and piroxicam in a double-blind trial results and methodological problems. Working Party of the Society for Rheumatology of the GDR for the Testing of Anti-rheumatic Drugs.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Tolera | 1984 |
[Treatment of chronic polyarthritis. Double-blind study with proglumetacin compared to diclofenac].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double | 1983 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Humans; Hydroxylation; Male; Middle Aged; Phenylacetates; | 1983 |
Comparison of the analgesic effect of ten nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Apazone; Arthritis, Rheumatoid; Aspirin; Carbazol | 1984 |
[Diclofenac in the treatment of progressive polyarthritis].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Humans; Male; Middle Aged; Phen | 1982 |
Diclofenac and ibuprofen in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Ib | 1980 |
[Current trends in pharmacotherapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind | 1980 |
[Cortisonoid sparing with the aid of sodium diclofenac in the treatment of rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind M | 1980 |
Diclofenac sodium (Voltaren) and ibuprofen in rheumatoid arthritis. A randomized double-blind study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Femal | 1980 |
[Comparative effectiveness of new antirheumatic drugs].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Flufenamic Ac | 1980 |
[Comparative efficacy of voltaren and naproxen in rheumatoid arthritis (double-blind trial)].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Dose-Response Relationship, Drug; Doubl | 1981 |
[Activity of diclofenac after a single, evening administration as compared with naproxen, in ambulatory patients with rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Humans; Male; Midd | 1981 |
[New drugs in the therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Humans; Levam | 1981 |
Diclofenac sodium and thyroid function tests.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; | 1982 |
[Clinical experiences with the new antirheumatic diclofenac].
Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Aspartate Aminotransferases; Clinical Tria | 1982 |
[Sodium diclofenac in the ambulatory therapy of joint inflammation and pain. Multicentric open-ended research performed by 223 Italian physicians].
Topics: Adult; Aged; Ambulatory Care; Arthritis; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 1982 |
Lymphocyte phenotype studies of rheumatoid arthritis patients treated with methotrexate.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; | 1994 |
A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial.
Topics: Acute-Phase Proteins; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Ar | 1995 |
Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cytokines; Data Interpretation, Stat | 1995 |
Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Combinations; Humans; Misoprostol; Oste | 1993 |
Review of the safety of diclofenac/misoprostol.
Topics: Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Humans; Misoprostol; Osteoarthritis; Safety; S | 1993 |
Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.
Topics: Arthritis, Rheumatoid; Diclofenac; Endoscopy, Gastrointestinal; Female; Humans; Incidence; Life Tabl | 1995 |
Double-blind comparison of the efficacy of diclofenac/misoprostol and diclofenac in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cohort Studies; Diclofenac; Double-Blind Method; Drug Combinations; Female; H | 1994 |
Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group.
Topics: Aged; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Mul | 1995 |
Comparative studies with tolfenamic acid in rheumatic disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Dru | 1994 |
Disappearance kinetics of solutes from synovial fluid after intra-articular injection.
Topics: Acetaminophen; Adult; Albumins; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chro | 1994 |
[Diclonate P in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Female; Humans; Injections, Intramus | 1994 |
[The effect of diclonate P on the clinical course of rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Diclofenac; Humans; Middle Aged; Remission Induction; Single-Blind Met | 1994 |
The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients.
Topics: Absorption; Adult; Aged; Arthritis, Rheumatoid; Biological Availability; Cholestyramine Resin; Diclo | 1994 |
A placebo-controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases.
Topics: Administration, Cutaneous; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Fema | 1993 |
Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study versus placebo in rheumatic patients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheu | 1993 |
Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Etodolac; Female; Humans; Male; Middle A | 1993 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 1993 |
Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Diclofenac; Humans; Osteoarthritis | 1993 |
Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1995 |
Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Female; Hum | 1995 |
The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis.
Topics: Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; El | 1996 |
A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Dose-Respon | 1995 |
Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, R | 1996 |
Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1996 |
Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Diclofenac; Doubl | 1996 |
Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclosporine; Diclofenac; Drug Combinations; Drug Interactions; | 1996 |
[The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1997 |
Ambulatory activity as an objective and quantifiable measure of nonsteroidal therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cros | 1998 |
Diclofenac/misoprostol: the European clinical experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Diclofenac; Doubl | 1998 |
[Effectiveness of vitamin E in comparison with diclofenac sodium in treatment of patients with chronic polyarthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Rheumatoid; Diclofena | 1998 |
The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthr | 1996 |
[Reducing pain by oral enzyme therapy in rheumatic diseases].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bromelains; Clinical Tr | 1999 |
[The effect of combined therapy on the ortofen concentration of the blood plasma and synovial fluid in patients with rheumatoid arthritis].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cimetidine | 1999 |
Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 2001 |
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase | 2002 |
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind | 2002 |
Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Indomethacin; Male | 1975 |
A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (nicoumalone).
Topics: Acenocoumarol; Angina Pectoris; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Interac | 1975 |
[Diclofenac in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Female; H | 1977 |
[Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Drug Tole | 1978 |
[Substitution of corticoids by diclofenac in the treatment of rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Female; H | 1978 |
Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Humans; Male; Middle Aged; Phen | 1978 |
A long-term study of diclophenac sodium in the treatment of rheumatoid arthritis and osteo-arthrosis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Cell Count; Blood Sedimentation; Chronic Disease; Clinical | 1978 |
A study of the anti-inflammatory effect of Voltaren in patients with rheumatoid arthritis.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Bli | 1978 |
Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: a double-blind multicentre study.
Topics: Adult; Aged; Ambulatory Care; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Bl | 1978 |
Diclofenac sodium (Voltaren) and naproxen in the treatment of rheumatoid arthritis: a comparative double-blind study.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Evalua | 1978 |
The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Central Nervous System; Clinical Trials as Topic; Diclofenac; Digestiv | 1978 |
[Use of vol'taren in rheumatological practice].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Humans; Middle Aged; O | 1978 |
[Comparative effectiveness of voltaren and indomethacin in rheumatoid arthritis (according to the data of a double-blind study)].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; | 1978 |
[Sodium dichlorophenylacetate in the treatment of rheumatoid arthritis in the aged].
Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Female; Humans; | 1978 |
A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Clinical Trials as | 1979 |
Diclofenac in rheumatoid disease.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Eval | 1979 |
Tolfenamic acid in the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; A | 1979 |
How long should long be? Long-term trials in rheumatic diseases.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Humans; Indomethacin; | 1979 |
[Results of treatment of rheumatoid arthritis with diclofenac].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Follow-Up Studies; Humans; Male | 1979 |
The value and results of long-term studies with diclofenac sodium (Voltarol).
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Tolerance; He | 1979 |
Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Hemoglobins; Human | 1979 |
Comparative clinical trials with diclofenac sodium (Voltarol) and naproxen in rheumatic conditions: investigation of possible changes in diclofenac dose and dose interval.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Tolerance; Female; Humans; Male; M | 1979 |
Analysis of the Brazilian literature on diclofenac sodium (Voltarol).
Topics: Arthritis, Rheumatoid; Brazil; Clinical Trials as Topic; Diclofenac; Drug Tolerance; Female; Humans; | 1979 |
A double-blind comparison of diclofenac sodium (Voltarol) and placebo in inpatients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Humans; J | 1979 |
Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Humans; Phenylacet | 1979 |
An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Drug Tolerance; Female | 1979 |
Diclofenac sodium (Voltarol): a double-blind comparative study with ibuprofen in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug | 1979 |
[Clinical experiences and results of clinical experimental studies with Voltaren in rheumatic diseases].
Topics: Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Diclofenac; DNA Repair; Drug Evalu | 1976 |
A clinical comparison of two leading non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cross-Over Studies; Diclofenac; Double-Blind Method; Female; Hum | 1991 |
Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis.
Topics: Administration, Oral; Arthritis, Rheumatoid; Cross-Over Studies; Delayed-Action Preparations; Diclof | 1991 |
The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diclofenac; Digestive S | 1992 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
Efficacy of Arthrotec in the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diclofenac; Dose-Respon | 1992 |
On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Combined Modality Therapy; Diclofenac; Female; Humans; Ibuprofen | 1992 |
A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diclofenac; Digestive System; Double-Blind Me | 1992 |
Cyclosporin and diclofenac interaction in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Pressure; Creatinine; Cyclosporins; Diclofenac; Drug Administrati | 1991 |
No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac.
Topics: Adult; Aged; Alprostadil; Arthritis, Rheumatoid; Creatinine; Diclofenac; Drug Therapy, Combination; | 1991 |
Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac | 1991 |
[The efficacy of immunomodulating therapy in rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Humans; Methot | 1990 |
Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Fe | 1990 |
[The dynamics of the analgesic effect of non-steroidal antirheumatic drugs. Ibuprofenlysinate versus diclofenac].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Humans; Ibuprofen; | 1989 |
International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac versus diclofenac: double-blind cross-over study in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Clinical | 1989 |
Effect sizes for interpreting changes in health status.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, St | 1989 |
Effect sizes for interpreting changes in health status.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, St | 1989 |
Effect sizes for interpreting changes in health status.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, St | 1989 |
Effect sizes for interpreting changes in health status.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, St | 1989 |
Sensitivity of a health status measure to short-term clinical changes in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; D | 1989 |
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1988 |
Comparison of efficacy of and tolerance to ketoprofen and diclofenac sodium in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Female; Humans; Ketopro | 1988 |
[Double-blind evaluation of SR-318, a sustained release preparation of diclofenac sodium, on rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Fe | 1988 |
A double-blind parallel group comparative study of lonazolac-calcium and diclofenac in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Ag | 1988 |
[Results of using the preparation Voltaren SR 100 in the treatment of rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Humans | 1987 |
Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation.
Topics: Adult; Aged; Alprostadil; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Dinoprost; | 1986 |
International experience with diclofenac in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Humans; I | 1986 |
Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1986 |
Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug | 1986 |
A study to determine the clinical relevance of the pharmacokinetic interaction between aspirin and diclofenac.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Drug | 1986 |
[Treatment of chronic polyarthritis with diclofenac. Crossover study with a new preparation form in comparison to the standard preparation].
Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Female; Humans; Long-Term Care; M | 1985 |
123 other studies available for diclofenac and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbonic Anhydrase Inhibito | 2018 |
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbonic Anhydrase Inhibito | 2020 |
Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients.
Topics: Arthritis, Rheumatoid; Diclofenac; Hexuronic Acids; Humans; Inflammation Mediators; Interleukin-22; | 2022 |
Lipoxygenase inhibitory synthetic derivatives of methyl gallate regulate gene expressions of COX-2 and cytokines to reduce animal model arthritis.
Topics: Animals; Arthritis, Rheumatoid; Cyclooxygenase 2; Cytokines; Diclofenac; Gene Expression; Lipoxygena | 2023 |
Influence of β-D-mannuronic Acid, as a New Member of Non-steroidal Anti- Inflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cells, Cultured; Chemokine CCL2; Diclofenac; Dose-R | 2021 |
[Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Male; Ru | 2020 |
Amelioration of autoimmunity and inflammation by zinc oxide nanoparticles in experimental rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Autoimmunity; Diclofenac; Freund's Adjuvant | 2021 |
Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, R | 2017 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2018 |
Effect of diclofenac etalhyaluronate (SI-613) on the production of high molecular weight sodium hyaluronate in human synoviocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Adhesion Molecules; Cells, Cult | 2019 |
Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Ca | 2013 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase | 2014 |
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2013 |
[Comparative study of the influence of melatonin and diclofenac on some hematologic indices of experimental rheumatoid arthritis in rats].
Topics: Animals; Animals, Outbred Strains; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Antibody Complex | 2014 |
How to mechanistically explain the CONDOR study data.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa | 2015 |
Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure.
Topics: Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofena | 2015 |
A pH-triggered delayed-release chronotherapeutic drug delivery system of aceclofenac for effective management of early morning symptoms of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Carrageenan; Diclofenac; Drug Delivery Systems | 2015 |
Efficacy of ultrasound mediated microbubbles in diclofenac gel to enhance transdermal permeation in rheumatoid arthritis induced rat.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental | 2015 |
Anti-inflammatory and anti-oxidative effects of herbal preparation EM 1201 in adjuvant arthritic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Experimental; Arthritis, | 2015 |
Efficacy of Combined Ultrasound-and-Microbubbles-Mediated Diclofenac Gel Delivery to Enhance Transdermal Permeation in Adjuvant-Induced Rheumatoid Arthritis in the Rat.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental | 2016 |
Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic attributes: a preclinical study.
Topics: Animals; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Edema; Humans; Inflammation | 2017 |
Pulsating back pain associated with tumor necrosis factor-alpha blockade.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2008 |
[The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary--a cross sectional non interventional study].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cross-Sectional Studies; Cyclooxygen | 2010 |
Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.
Topics: Animals; Arthritis, Rheumatoid; Bone Marrow Cells; Cell Migration Inhibition; Cells, Cultured; Diclo | 2010 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni | 2010 |
[Unilateral odynophagia in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis, | 2011 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
Effects of methotrexate on the expression of the translational isoforms of glucocorticoid receptors α and β: correlation with methotrexate efficacy in rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blottin | 2011 |
[Pharmacia and Pfizer on the CLASS trial: criticism doesn't give a fair picture of the results].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Controlled Cli | 2002 |
Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Contraindications; Cyclooxygenase In | 2003 |
Aphthous colitis induced by non-steroidal antirheumatic drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Colitis | 2003 |
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
[A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Colectomy; Colitis, Ischemic; Colon; | 2004 |
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Clinical Trials, Phase II as T | 2005 |
Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis.
Topics: Animals; Arthritis, Rheumatoid; Diclofenac; Drug Delivery Systems; Liposomes; Rabbits; Radionuclide | 2005 |
Optimization of pulsed electromagnetic field therapy for management of arthritis in rats.
Topics: Acid Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthrit | 2005 |
Anti-tumor necrosis factor-alpha-induced psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Etanercep | 2006 |
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Analgesic, antipyretic and Ulcerogenic properties of an indigenous formulation--Kalpaamruthaa.
Topics: Analgesics; Analgesics, Non-Narcotic; Animals; Arthritis, Rheumatoid; Diclofenac; Dinoprostone; Fema | 2007 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; | 2007 |
[Coronary risks with NSAID and coxibs. The end of hysteria].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause | 2006 |
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen | 2006 |
Enhanced efficacy of diclofenac sodium-loaded lipogelosome formulation in intra-articular treatment of rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemistry, Pharmaceutical; | 2008 |
Drug-induced bullous dermatosis with linear IgA deposits along the basement membrane.
Topics: Arthritis, Rheumatoid; Basement Membrane; Diclofenac; Drug Eruptions; Female; Fluorescent Antibody T | 1981 |
[Extra-membranous glomerulonephritis during the treatment of rheumatoid polyarthritis with diclofenac].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Glomerulonephritis; Humans; Middle Aged; Phenylacetates | 1984 |
[Effect of indomethacin and diclofenac on plasma and synovial prostaglandins in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Diclofenac; Dinoprost; Humans; Indomethacin; Phenylacetates; Prostaglandin An | 1983 |
The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Chromatography, Gas; Delayed-Action Prepar | 1982 |
Diclofenac sodium, diflunisal and naproxen: patient preferences for anti-inflammatory drugs in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Consumer Behavior; Diclofenac; Diflunisal; Female; Humans; Male; | 1982 |
Voltarol 50mg in arthritis: a dosage study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Drug Administration Schedule; Drug Toler | 1982 |
[Comparison of 3 therapeutic regimes using non-steroidal antirheumatic agents in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Humans; Male; Middle Aged; Naproxen; Phenylacetates; Supp | 1981 |
[Membranous glomerulonephritis during rheumatoid arthritis. Probable toxicity of diclofenac (author's transl)].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Glomerulonephritis; Humans; Middle Aged; Phenylacetates | 1980 |
[Influence of various non-steroid antirheumatic drugs on the electric potential between the gastric serosa and mucosa (author's transl)].
Topics: Anti-Inflammatory Agents; Apazone; Arthritis, Rheumatoid; Diclofenac; Female; Gastric Mucosa; Humans | 1981 |
[Double blind cross-over study with lonazolac-Ca and diclofenac-Na in 30 patients with chronic polyarthritis].
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diclofenac; Double-Blind Met | 1981 |
[Extramembranous glomerulonephritis in rheumatoid arthritis. Possible role of diclofenac].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Glomerulonephritis; Humans; Middle Aged; Phenylacetates | 1980 |
An interim report on a multicentre general practice study of Voltarol. 1) Rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Family Practice; Female; Humans; Male; M | 1980 |
[Hematotoxic lesions caused by non-steroidal antirheumatic agents].
Topics: Adult; Aged; Agranulocytosis; Anemia, Aplastic; Arthritis, Rheumatoid; Aspirin; Diclofenac; Female; | 1980 |
Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Ar | 1994 |
[Are right colonic lesions specific to sustained-release NSAID preparations?].
Topics: Aged; Arthritis, Rheumatoid; Cecal Diseases; Colonic Diseases; Delayed-Action Preparations; Diclofen | 1994 |
Safety profile of etodolac in the elderly population.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Dic | 1994 |
[Rheumatoid arthritis of the hand. The initial results with 31-phosphorus MR spectroscopy].
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Female; Hand; Hand Deformities; Humans; Joints; Magn | 1994 |
In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Bone and Bones; Cartilage, Articular; Chondrocalcinosis; Culture T | 1993 |
Tenidap versus diclofenac in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Humans; Indoles; Oxindol | 1996 |
Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blotting, Northern; Cells, Cultured; | 1996 |
Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells, Cultured; Chromatography, Thi | 1997 |
Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Collagenases; Cyclooxygenase Inhibitors; Diclofenac; Dinopro | 1997 |
Bone marrow infection caused by Actinobacillus ureae in a rheumatoid arthritis patient.
Topics: Actinobacillus; Actinobacillus Infections; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1997 |
[Vitamin E in rheumatic disease therapy?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Rheumatoid; Diclofenac; Humans; Os | 1998 |
[Tiopronin-induced nephrotic syndrome with minimal glomerular lesions].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Diclofenac; Dose-R | 1999 |
Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blotting, Western; Cells, Cultured; | 1999 |
Colitis induced by interaction of cyclosporine A and non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Child; Colitis; Cyclosporine; Diclof | 1999 |
Aceclofenac: is the antiinflammatory effect really due to cyclooxygenase inhibition?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells, Cultured; Chondrocytes; Diclo | 1999 |
Study of efficacy and tolerance of ketoprofen and diclofenac sodium in the treatment of acute rheumatic and traumatic conditions.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Ketoprofen; Male; Middle | 1998 |
Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumat | 1999 |
Bilateral atraumatic dislocation of the shoulder.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Ra | 1999 |
[Arthrotec treatment of rheumatoid arthritis].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofe | 2000 |
A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Dinoprostone; Enzyme Pre | 2000 |
Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Female; Humans; I | 2000 |
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal | 2000 |
[Approaches to prediction of gastropathy development risk due to non-steroidal antiinflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Gastric Acid; Gastric Mu | 2000 |
[Topical administration is better than oral administration].
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, R | 2001 |
Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Health Care Costs; Human | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida | 2001 |
Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 2001 |
Diclofenac (Voltarol) in the treatment of rheumatic diseases. A conspectus of international experiences: Proceedings of an international symposium, Tangier, March 1978.
Topics: Animals; Arthritis, Rheumatoid; Congresses as Topic; Diclofenac; Humans; Phenylacetates | 1979 |
Pharmacological properties of diclofenac sodium and its metabolites.
Topics: Animals; Arthritis, Rheumatoid; Chemical Phenomena; Chemistry; Cyclooxygenase Inhibitors; Diclofenac | 1978 |
A review of spontaneously reported adverse drug reactions with diclofenac sodium (Voltarol).
Topics: Adult; Aged; Anticoagulants; Arthritis, Rheumatoid; Blood Cell Count; Central Nervous System; Diclof | 1979 |
Long-term tolerability study of Voltaren.
Topics: Adult; Aged; Arthritis; Arthritis, Rheumatoid; Blood Cell Count; Blood Proteins; Diclofenac; Female; | 1975 |
[Evaluation of parameters of inflammation in the clinical trial of sodic diclofanac in rheumatology].
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Drug Evaluation; Female; Humans; Middle Aged; Osteoa | 1977 |
[Voltaren in the treatment of rheumatic diseases].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Male; Phenylacetates; Rheumati | 1977 |
[Therapeutic efficacy and tolerance of a new drug, sodium diclofenac, in inflammatory and metabolic rheumatism].
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Drug Evaluation; Female; Gout; Humans; Male; Middle | 1978 |
Comparisons of tolerability findings in international clinical trials.
Topics: Arthritis, Rheumatoid; Aspirin; Cardiovascular System; Clinical Trials as Topic; Diclofenac; Drug To | 1979 |
[A new nonsteroid antirheumatic drug diclofenac in the treatment of rheumatoid arthritis (preliminary report].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Humans; Male; Middle Aged; Phenylacetates | 1977 |
[Endoscopic evaluation of the gastric tolerance of sodium diclofenac in high doses].
Topics: Arthritis, Rheumatoid; Diclofenac; Female; Gastroscopy; Gout; Humans; Joint Diseases; Male; Middle A | 1978 |
Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Gastr | 1992 |
Transdermal absorption of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients: I. Diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid | 1992 |
Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy; Chemical and Drug Ind | 1992 |
Diclofenac inhibits monocyte superoxide production ex vivo in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Diclofenac; Female; Fluorides; Humans; Middle Aged; Monocytes; Superox | 1991 |
Chondroprotection, myth or reality: an experimental approach.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage, Articular; Cells | 1990 |
Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Dicl | 1991 |
Duodenal diverticulum complicated by duodenal inflammation and obstruction secondary to the use of the NSAID diclofenac.
Topics: Aged; Anastomosis, Surgical; Arthritis, Rheumatoid; Diclofenac; Duodenal Obstruction; Humans; Male; | 1991 |
Diclofenac-associated hepatotoxicity.
Topics: Aged; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Diclofenac; Female; Fibromyalgi | 1990 |
[Urinary calculus protective side effects of anti-rheumatic therapy].
Topics: Arthritis, Rheumatoid; Calcium; Calcium Oxalate; Diclofenac; Follow-Up Studies; Humans; Indomethacin | 1990 |
[The nephrotic syndrome as a consequence of Feloran treatment in a female patient with rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Chronic Disease; Diclofenac; Female; Humans; Nephrosis, Lipoid; Nephrot | 1990 |
[The anti-inflammatory drug diclofenac].
Topics: Animals; Arthritis, Rheumatoid; Chronic Disease; Diclofenac; Glomerulonephritis; Humans; Mice; Posto | 1989 |
[Some features of the effect of voltaren on the coronary blood flow in patients with rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Coronary Circulation; Diclofenac; Electrocardiography; Female; Humans; | 1989 |
Effects of diclofenac, indomethacin, tolfenamic acid and hydrocortisone on prostanoid production in healthy and rheumatic synovial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Humans; Hydrocortisone; | 1989 |
Monocytes and granulocytes in rheumatoid arthritis (RA): phagocytic activity and superoxide anion production.
Topics: Adolescent; Adult; Aged; Animals; Anions; Arthritis, Rheumatoid; Cattle; Diclofenac; Dimercaprol; Gl | 1985 |
[Unwanted modification of the thyroid gland by drugs with special reference to nonsteroidal antirheumatic agents].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Female; Goit | 1986 |
[Clinical pharmacology of the new Soviet anti-inflammatory preparation ortofen].
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Diclofenac; Drug Evaluation; Drug Tolerance; Half-Life; | 1988 |
[Topical use of Rheumon-Gel in the combined treatment of patients with rheumatoid arthritis].
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diclofenac; Drug Ev | 1987 |
Water intoxication associated with non-steroidal anti-inflammatory drug therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Female; Humans; Hy | 1987 |
[Different effects of diclofenac and ketoprofen on the bactericidal action of polynuclear neutrophils in rheumatoid polyarthritis].
Topics: Arthritis, Rheumatoid; Blood Bactericidal Activity; Diclofenac; Humans; Ketoprofen; Neutrophils; Phe | 1987 |
[Diclofenac-Na--an alternative treatment possibility in therapy-resistant calcium oxalate urolithiasis?].
Topics: Adult; Aged; Arthritis, Rheumatoid; Calcium Oxalate; Diclofenac; Female; Humans; Kidney Calculi; Mal | 1986 |
Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspiri | 1985 |
Effects of Voltaren on arachidonic acid metabolism in arthritis patients.
Topics: Arachidonic Acid; Arachidonic Acids; Arthritis, Rheumatoid; Diclofenac; Dinoprostone; Humans; Hydrox | 1985 |
Non-steroidal anti-inflammatory drugs and adverse renal effects.
Topics: Aged; Arthritis, Rheumatoid; Diclofenac; Humans; Kidney Diseases; Male; Phenylacetates | 1985 |
[Use of slow-release sodium diclofenac in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Drug Administration Schedule; Drug E | 1985 |
[In vitro effects of non-steroidal anti-inflammatory drugs on production of oxygen radicals evaluated by the chemiluminescent response of polymorphonuclear leukocytes].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Cell Membrane; Diclofenac; Free Radicals; | 1985 |
Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Humans; Kinetics; Metabolic Clearance Rate; Middle A | 1985 |
Worldwide experience with diclofenac in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Humans; Indomethacin; Naproxen; Ost | 1985 |
Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mi | 1985 |